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Cellular senescence is important in tumor suppression. However, the 
molecular mechanisms and cellular regulators of senescence are not 
completely understood. Several recent studies have suggested that Sharp-1, a 
basic helix-loop-helix (bHLH) transcription factor, may function as a potential 
tumor suppressor. Consistent with this notion, our laboratory previously has 
shown that overexpression of Sharp-1 induces cell cycle arrest in fibroblast 
cells and also renders cells’ resistance to apoptosis. Since cell cycle arrest and 
reduced apoptosis are apparent in senescent cells, we examined the potential 
role for Sharp-1 in induction of cellular senescence. Here we show that 
overexpression of Sharp-1 is able to induce growth arrest and premature 
senescence in mouse fibroblast cells. This is accompanied by increased 
intracellular ROS production, specifically H2O2 and elevated acetyl and total 
p53 levels. Sirt1, a NAD
+
 dependent class III histone deacetylase (HDAC), 
has the opposite impact and inhibits cellular senescence by scavenging H2O2 
as well as by deacetylating p53 to inhibit p53 mediated functions. Thus, we 
hypothesized that Sirt1 may antagonize Sharp-1 induced senescence. 
Moreover, since previous studies have established that Sharp-1 can interact 
with Sirt1, we have also explored the regulatory connection between Sharp-1 
and Sirt1 in senescence. We show that increasing Sirt1 activity using 
resveratrol or increasing its expression in Sharp-1 overexpressing cells inhibits 
Sharp-1 mediated senescence concomitant with deacetylation of p53 at lysine 
379 (K379). Though Sirt1 is able to counteract Sharp-1 mediated p53 
regulation and function, neither Sirt1 nor Sharp-1 regulates each other at the 
transcriptional level. Co-immunoprecipitation and GST pull-down assays 
xii 
 
demonstrate that Sharp-1 directly interacts with Sirt1 and this association 
weakens upon cellular stress. Similarly, binding between Sirt1 and p53 also 
weakens upon DNA damage, but not the association between Sharp-1 and p53. 
This suggests that Sirt1 antagonizes Sharp-1 to modulate p53 activity via 
regulation of protein-protein interaction. Taken together, these findings 
provide new insights into antagonistic mechanisms between Sharp-1 and Sirt1 
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1. Introduction 
1.1 Sharp-1: Structure and Transcriptional properties 
Basic helix-loop-helix (bHLH) proteins are transcription factors important in 
developmental processes such as cell differentiation and metabolism (Massari 
and Murre, 2000). Within this large superfamily, members of bHLH-Orange 
(bHLH-O) proteins are known to function as transcription repressors, and 
based on structural and phylogenetic analysis, bHLH-O transcription 
repressors are grouped into four subfamilies: Hes, Hey, Helt and Stra13/Dec 
(Sun et al., 2007; Fujimoto et al., 2007). Based on sequence alignment of 
DNA binding sites and presence of conserved domains, human Dec 
(Differentially expressed in chondrocytes), mouse Stra13 (Stimulated with 
retinoic acid 13) and rat Sharp-1 (Enhancer-of-Split and hairy-related protein) 
are categorized within the Stra13/Dec subfamily of bHLH-O proteins (Li et al., 
2003; Azmi et al., 2003). There are two members of Stra13/Dec subfamily, 
namely Stra13 and Sharp-1(Sun et al., 2007).  
Sharp-1/Dec2/bHLHB3/BHLHE41 is a 410 amino acid containing 
transcription factor that was first cloned from adult rat brain based on its 
homology to Drosophila Hairy and Enhancer–of-split (Rossner et al., 1997). 
Sequence alignment showed that Sharp-1 only shared 42% homology to 
enhancer-of-split and 37% homology to Hairy proteins in the bHLH domains. 
However, Sharp-1 and Stra13 have 96% sequence identity in their bHLH 
domain and 50% homology over the entire length (Azmi et al., 2003).  
Similar to Hairy and E(Spl) members, the basic domain in Sharp-1 is 
responsible for DNA binding and the adjacent helix-loop-helix domain is 
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required for homo- or hetero- dimerization.  In addition, Sharp-1 also contains 
a 35 amino acid motif known as “orange domain” which is located at the C-
terminal of the bHLH domain (Li et al., 2003). Though the exact function of 
orange domain is not clearly understood, it is believed it might provide a 
protein-protein interaction interface (Dawson et al., 1995), and thus play a 
structural role which is necessary for repression (Eastwood et al., 2013). 
 
Figure 1.1 Schematic diagram on structures of 13 mammalian bHLH-O 
factors. Sharp-1/Dec2 is classified under Stra13/Dec sub-family which only 
has two proteins: Stra13 and Sharp-1. (Adapted from Sun H, Ghaffari S and 
Taneja R. bHLH-Orange transcription factors in development and cancer. 
Translational Oncogenomics. 2007; 2: 105-118 ) 
 
 
Like Hes and Hey proteins, Sharp-1/Dec2 binds to class B E-box site 
CACGTG with high affinity (Azmi et al., 2003). However, in contrast to 
members from other subfamilies, Sharp-1/Dec2 lacks the WRPW motif in the 
C-terminus that is required to recruit the co-repressor Groucho for 
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transcriptional repression (Fisher et al., 1996). Instead, Sharp-1 acts as 
transcriptional repressor by recruiting co-repressors HDAC1, Sirt1 and G9a 
(Fujimoto et al., 2007; Ling et al., 2012). In addition, Sharp-1 can also inhibit 
transcription activity through interacting with other proteins. For example, 
Sharp-1 binds and inhibits transcription activity of MyoD which leads to 
inhibition of skeletal muscle differentiation (Azmi et al., 2004; Fujimoto et al., 
2007). Similarly, Sharp-1 also interacts and represses the transcription activity 
of C/EBPα and C/EBPß resulting in inhibition of adipogenesis (Gulbagci et al., 
2009).  
1.1.1 Sharp-1: Chromosomal location and expression 
The Sharp-1 gene is located on mouse chromosome 6G2-G3, rat chromosome 
4q43 distal-q4 and human chromosome 12p11.23-p12.1 (Fujimoto et al., 2001; 
Yamada and Miyamoto; 2005). It is expressed at high levels in the skeletal 
muscle and brain, moderate levels in the heart and pancreas, low levels in lung 
and placenta and is barely detectable in kidney and liver (Fujimoto et al., 2001, 
Azmi et al., 2003).  
1.1.2 Sharp-1: Regulation and Functions in Cellular Differentiation and 
Circadian Regulation 
Studies have demonstrated Sharp-1 functions as a negative regulator in cell 
differentiation as overexpression of Sharp-1 inhibits both myogenesis (Azmi 
et al., 2003; Azmi et al., 2004; Ling et al., 2012; Wang et al., 2013) and 
adipogenesis (Gulbagci et al., 2009). Moreover, Sharp-1 is also found to play 
an important role in circadian rhythm regulation in the suprachiasmatic 
nucleus (SCN) of the hypothalamus. Rossner et al reported that Sharp-1 
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deficient mice displayed significantly slowed behavioral re-entrainment to the 
delayed LD cycle (12 hr light/12 hr dark) but not phase shifting behavior when 
compared to wild type controls (Rossner et al., 2008). Moreover, Clock/Brain-
muscle-arnt-like-protein1 (Bmal1) is known to regulate circadian rhythm and 
its induced transactivation of the Period 1 (Per1) is repressed by direct 
association with Dec2 or competition for the E-box element. Dec2 expression 
is also controlled by the clock genes via autoregulatory feedback loop. 
Therefore, Dec2 plays a negative role in circadian-dependent gene expression 
(Hamaguchi et al., 2004; Honma et al., 2002).  
Kijima’s group proposed that human Dec2 can play an important role in the 
cross-talk between circadian regulation and the response to hypoxia (Sato et 
al., 2008). This is because previously it was reported that human Dec2 mRNA 
level was increased under hypoxia as Dec2 is the direct target of hypoxia-
inducible factor-1 (HIF-1) (Miyazaki et al., 2002), which is a transcription 
factor that regulates gene expression induced by hypoxia (Forsythe et al., 
1996). Vascular endothelial growth factor (VEGF) on the other hand, is a 
major cytokine that can be induced by hypoxia and its gene expression is also 
regulated by circadian rhythms (Koyanagi et al., 2003). Kijima’s group 
showed that Dec2 repressed VEGF gene expression under hypoxic condition. 
In addition, VEGF and Dec2 showed opposite circadian oscillation patterns in 
cartilage. Hence, it is likely that Dec2 might play a role in VEGF involved 
pathologies (Sato et al., 2008) such as tumor cell growth (Kim et al., 1993).  
1.1.3 Sharp-1 Function in Cell Cycle Arrest, Apoptosis and 
Tumorigenesis 
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Sharp-1 expression has been reported to be high in normal tissues and down-
regulated in tumors (Sato et al., 2008; Falvella et al., 2008; Wang et al., 2011; 
Sato et al., 2012), which suggests a potential tumor suppressor role for Sharp-
1. Findings from Dragani’s group showed that Sharp-1 transcripts were low in 
human lung cancer cell lines as well as in human lung adenocaricinomas as 
compared to normal lung tissue. In addition, overexpression of Sharp-1 
blocked colony formation in lung cancer cell line (Falvella et al., 2008). 
Moreover, overexpression of Sharp-1/Dec2 represses cyclin D1 expression 
which prevents cell proliferation in human mammary epithelial cells (Li et al., 
2010).  
Recent data from our lab reported that Sharp-1 mRNA level is enhanced by 
genotoxic agents and ectopic expression of Sharp-1 leads to S and G2/M cell 
cycle arrest. Sharp-1 overexpressing cells also have reduced apoptotic 
response when exposed to DNA damaging drugs (Liu et al., 2010). 
Overexpression of Dec2 resulted in reduced amount of cleaved PARP and 
caspase-8 which prevented cells from undergoing apoptosis (Liu et al., 2010). 
Consistent with these studies, Sharp-1 was found to exhibit an anti-apoptotic 
effect in breast cancer MCF-7 cells. siRNA mediated knockdown of Dec2 led 
to a significant increase in apoptosis compared with scrambled siRNA. 
Overexpression of Dec2 was found to result in reduced amount of cleaved 
PARP (Liu et al., 2010), and Wu et al later reported similar observations in 
breast cancer MCF-7 cells treated with anti-tumor drug-paclitaxel. They 
demonstrated that Dec2 expression was enhanced in MCF-7 cells treated with 
paclitaxel and knockdown of Dec2 increased the amount of cleaved PARP in 
both presence and absence of paclitaxel (Wu et al., 2011). This confirmed the 
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anti-apoptotic effects of Sharp-1 in breast cancer cells. Thus overexpression 
and knockdown studies of Dec2 have indicated that Dec2 is able to affect the 
expression levels of apoptosis related factors such as Bim, Bax, Fas, caspase-8, 
VEGF as well as the amount of cleaved caspases and cleaved poly (ADP-
ribose) polymerase (PARP) (Sato et al., 2008; Liu et al., 2010). 
Recent studies have also shown that Sharp-1 suppresses breast cancer 
metastasis by binding to HIFs and promotes HIF proteosomal degradation 
(Montagner et al., 2012). This further supports a tumor suppressor role for 
Sharp-1. However, the mechanisms by which it functions as a tumor 
suppressor are still poorly understood.  
1.2 Cellular Senescence 
Cellular senescence is an important process which induces irreversible growth 
arrest, yet cells remain metabolically active (Campisi and d’Adda di Fagagna, 
2007; Serrano et al., 1997). Hayflick and Moorhead first described the 
observation that normal human diploid fibroblasts grown in culture conditions 
would stop replication after a finite number of cell divisions (Hayflick and 
Moorhead, 1961). This phenomenon was later termed as “replicative 
senescence” and the number of cell divisions before cells enter senescent state 
was known as “Hayflick limit” (de Magalhaes, 2004). Over the past few 
decades, cellular senescence has been studied intensively. Senescence was 
observed in premalignant lesions in both humans and mice but was absent 
from the counterparts of those transformed lesions (Collado et al., 2005). 
Hence, cellular senescence has been recognized as an important tumor 
suppressive mechanism due to its ability to halt the growth permanently 
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(Sager, 1991; Campisi, 2001). In recent years, more studies have focused on 
the relationship between cellular senescence and ageing as aged organisms 
accumulate more senescent cells (Berube et al., 1998) and senescence prevents 
regenerative cells from proliferating (Ito et al., 2006). It seems like cellular 
senescence acts as a double-edged sword as it is beneficial for tumorigenesis 
suppression but detrimental in ageing process (Chuaire-Noack et al., 2010). 
Therefore, it is important to understand the underlying mechanisms and 
consequences of cellular senescence in order to amplify its benefits and 
minimize its damages.     
1.3 Characteristics of Senescent Cells 
No single biomarker has been identified so far that is specific for all senescent 
cells and not all senescent cells display all the possible senescence markers. 
Therefore, a number of criteria are used as guideline to identify senescent cells. 
1.3.1 Growth Arrest 
Cellular senescence is induced by various extrinsic and intrinsic factors that 
could potentially cause damage in cells. Senescence is believed to be an 
irreversible process in which cells are permanently arrested at G1 phase due to 
the expression of cell-cycle inhibitors that have the ability to inhibit the cell 
cycle. As a result, proliferation does not resume even in the presence of 
appropriate growth factors (Narita, 2007). However, recent studies suggested 
that cellular senescence could also be induced with a G2-M arrest (Mao et al., 
2012) and it was possible to reverse the process and resume proliferation 
through multiple ways. For instance, inactivation of major pathways or 
interleukins could cause reversal of senescence (Beausȇjour et al., 2003; 
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Coppȇ et al., 2008). Thus, irreversible growth arrest should not be used as a 
sole biomarker to detect senescence even though it is an important hallmark 
for senescence.  
1.3.2 Morphology of Senescent Cells 
Cells exhibit specific morphological changes when they undergo cellular 
senescence.  For example, senescent fibroblast cells change their shapes from 
spindle form to being more flattened, enlarged with an increase in size of 
nucleus and nucleoli (Matsumura, 1980; Galloway and Buckton, 1978; Chen 
et al., 2000); cytoplasmic granularity (Zhang and Yang, 2011; Mooi and 
Peeper, 2006) as well as number of lysosomes and Golgi bodies (Maciera-
Coelho et al., 1971). Senescent cells also display vacuoles in both cytoplasm 
and endoplasmic reticulum (Brandes et al., 1972).  
1.3.3 Resistance to apoptosis 
There are two major mechanisms to stop growth in response of cellular 
stresses: cellular senescence and apoptosis. The major difference between 
these two processes is that senescence irreversibly stops growth of cells which 
are stressed or damaged, whereas apoptosis eliminates cells which are 
potentially cancerous (Green and Evan, 2002). Previous studies have 
demonstrated that senescent cells are resistant to apoptosis. For example, 
human fibroblast cells in vitro undergo senescence when treated with sub-
lethal level of H2O2 or when serum is removed from culture medium as they 
display a predominant G1 phase arrest, increased p21
Cip1
 level, decreased Bax 
protein solubility and unchanged level of Bcl2. On the other hand, apoptotic 
cells show mainly S phase cell cycle distribution, absence of p21
Cip1
 protein, 
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increased Bax solubility and reduced level of Bcl2 (Chen et al., 2000; Wang, 
1995). While it is not known how cells decide whether to undergo senescence 
or apoptosis, factors that may affect these decisions include cell type, the 
nature and intensity of stress, survival stimuli, oncogenic status as well as p53 
expression (Rebbaa et al., 2003; Sionov and Haupt, 1999). 
1.3.4 Change in Gene Expression Patterns 
Altered gene expression patterns are observed in senescent cells compared to 
normal cells or quiescent cells (Fridman and Tainsky, 2008; Shelton et al., 





, which are usually not expressed in quiescent cells 
(Brenner et al., 1998; Serrano et al., 1997; Braig and Schmitt; 2006). These 
two proteins are cyclin-dependent kinase inhibitors (CDKIs) which are 
involved in tumor suppressive pathways that are controlled by retinoblastoma 
(pRB) and p53, respectively. p21
Cip1
 is directly activated by p53 (Xiong et al., 
1993; Jackson and Pereira-Smith, 2006), whereas p16
INK4a
 is important in 
regulating pRB (Serrano et al., 1993). In addition, genes that encode proteins 
to promote cell cycle progression, such as cyclin A, cyclin B and proliferating 
cell nuclear antigen (PCNA), are repressed in senescent cells (Stein et al., 
1991; Pang and Chen, 1994). Other than change of cell cycle genes, senescent 
cells also overexpress secreted degradation enzymes and cytokines (Itahana et 
al., 2004), which have the ability to change tissue microenvironment 
(Trougakos et al., 2006; Zhang et al., 2003).  
1.3.5 Senescence-Associated ß-Galactosidase Activity 
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The very first marker which was used to identify senescent cells is senescence-
associated ß-galactosidase (SA-ß-gal) (Dimri et al., 1995). It was reported that 
ß-galactosidase could be detected using histochemical staining at pH6 and 
positive senescent cells produce a blue perinuclear staining (Lee et al, 2006). 
SA-ß-gal activity was derived from the acidic lysosomal ß-galactosidase 
(pH4.5) as this activity could only be detected at a near neutral pH (pH6) in 
senescent cells due to the expansion of the lysosomal compartment as well as 
increased lysosomal mass (Kurz et al., 2000; Yang and Hu, 2005). Even 
though reports suggested that increased SA-ß-galactosidase activity might not 
be specific for senescence (Cristofalo, 2005; Lee et al., 2006; Untergasser et 
al., 2003), it is still used extensively as an easy and rapid method to detect 
senescence.  
1.3.6 Senescence-Associated Heterochromatin Foci (SAHF) 
Senescent cells in culture have altered chromatin structure, which can be 
detected by DAPI staining within nuclei. Generally, normal cells show 
homogenous DAPI staining. However, in senescent cells, remodeling of 
chromatin causes formation of heterochromatin known as senescence-
associated heterochromatin foci (SAHF) (Narita et al., 2006; Zhang et al., 
2007). SAHF display preferential binding with DAPI, leading to bright and 
punctuate DNA foci. In addition, several common markers for 
heterochromatin can be found in SAHF, including heterochromatin protein-1 
(HP1) and heterochromatin–associated histone modifications, such as enriched 
acetylation or methylation of Lys9 on histone H3 (Narita et al., 2003). 
Moreover, heterochromatic foci are involved in suppression of cell cycle 
machinery, such as E2F transcription factors. In senescent cells, pRB recruits 
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heterochromatin proteins to the promoter of E2F target genes to form SAHF, 
which represses these pro-proliferative genes and induces senescence (Narita 
et al., 2003). 
1.3.7 Senescence-Associated DNA Damage Foci (SDF) 
Besides SAHFs, senescent cells are also identified by the presence of 
senescence-associated DNA-damage foci (SDFs) (Herbig et al., 2004; Takai et 
al., 2003). However, unlike SAHFs, SDFs are present in senescent cells that 
express proteins associated with DNA damage response (DDR) (d’Adda di 
Fagagna et al., 2003). 
1.3.8 Senescence-Associated Secretory Phenotype (SASP) 
Senescent cells in response to DNA damage often display changes in various 
secreted factors, such as proinflammatory cytokines, chemokines, growth 
factors, proteases (Rodier et al., 2009), they are collectively known as 
senescence-associated secretory phenotype (SASP) (Coppȇ et al., 2008). Some 
of the SASP factors, such as proinflammatory cytokines promote 
tumorigenesis with enhanced proliferative rate and invasion of premalignant 
cells (Parrinello et al., 2005), whereas others, such as IL-6 or IL-8, are 
important in maintenance of senescence (Wajapeyee et al., 2008). On the other 
hand, SASPs also trigger innate immune response, resulting in clearance of 
senescent cells which is beneficial for tumor suppression (Xue et al., 2007). 
Due to both pro-tumorigenic and anti-tumorigenic effects of SASP, multiple 
factors are usually used together with this to identify senescence.  
1.4 Causes of Cellular Senescence 
- 12 - 
 
Over the past decades, many studies have been carried out to understand the 
causes and underlying mechanisms of cellular senescence. Telomere 
shortening was the first cause discovered to drive certain types of cells to 
undergo senescence (Harley et al., 1990; Bodnar et al., 1998). Studies later 
suggested that senescence could be induced by various types of extrinsic 
stimuli which are independent of telomere shortening. This includes DNA 
damage, chromatin structure perturbation, oxidative stress as well as oncogene 
overexpression (Serrano and Blasco, 2001; Lloyd, 2002; Serrano et al., 1997). 
1.4.1 Replicative Senescence 
Since the first description of cellular senescence, the term “replicative 
senescence” is used for the phenomenon whereby senescence is achieved as a 
result of cell replication which causes telomere attrition (Allsopp et al., 1992).  
1.4.1.1 Telomere Shortening 
Telomere, the repetitive guanine rich sequence (5’-TTAGGG-3’), is a 
structure which protects chromosome ends in eukaryotes from degradation or 
fusion by DNA nuclease (d’Adda di Fagagna et al., 2004). In human germ 
cells, the enzyme telomerase maintains the length of telomeres. However, in 
somatic cells, telomerase activity is too low to maintain telomere length. As a 
result, a gradual decrease of telomere length is observed during each round of 
replication (Ohmura et al., 1995). When the length of telomere is shortened 
below the threshold or when telomere is dysfunctional, it leads to genomic 
instability and DNA damage foci formation which then initiates DNA damage 
response (DDR) (d’Adda di Fagagna et al., 2003; Fumagalli et al., 2012; 
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Carneiro et al., 2010) that triggers p53-mediated senescence (Gorbunova et al., 
2002).  
1.4.2 Premature Senescence 
Besides replicative senescence that occurs due to shortening of telomere, 
senescence can be induced by various factors without any telomere shortening 
or dysfunction and it is referred as “premature senescence” (Chen et al., 2001).  
1.4.2.1 DNA-Damage-Initiated Senescence 
DNA damage, caused by multiple intrinsic and extrinsic factors affects the 
stability and integrity of chromosomes (Shiloh, 2006). When DNA damage is 
recognized, DDR occurs to fix the damage by DNA repair machinery when 
the damage is mild, or induces cells to undergo premature senescence or 
programmed cell death when the damage cannot be repaired (Nakamura et al., 
2008). Hence, there are two types of DDR mediated senescence: one is 
telomere-dependent DDR triggered by shortening of chromosomal ends and 
the other is telomere-independent DDR induced by factors such as ionizing 
radiation (Robles and Adami, 1998) and chemotherapeutic drugs (Roninson, 
2003) that cause DNA double strand breaks and eventually result in cellular 
senescence in both normal and tumor cells (Chang et al., 2002; Novakova et 
al., 2010).  
1.4.2.2 Altered Chromatin Structure induced Senescence 
Epigenetic modifications on chromosomes, such as histone acetylation and 
methylation, are able to change chromatin structure, gene expression and 
genome stability (Margueron et al., 2005) which play major role in senescence. 
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For instance, human fibroblasts treated with histone deacetylase inhibitors 
Trichostatin A (TSA) or sodium butyrate induce a senescence like state 
(Ogryzko et al., 1996). This suggests that modulating histone acetylation in 
cells is important for induction of senescence. Similarly, EZH2, a histone 
methyltransferase, represses INK4a locus in normal proliferating cells. 
However, when senescence is triggered by various stimuli, EZH2 levels drop 
with reduced methylation of H3K27 at the INK4a locus. As a result, INK4a is 
functional and is able to induce senescence in cells (Bracken et al., 2007).  
1.4.2.3 Reactive Oxygen Species 
Over the past decade, various groups have demonstrated that senescence could 
be either induced by increasing intracellular reactive oxygen species (ROS) or 
triggered by exogenous ROS. ROS induces senescence through multiple ways. 
For example, when cells are exposed to sub-lethal concentrations of H2O2 or 
overexpress oncogenes such as Ras, p53 is up-regulated, which in turn induces 
p21
Cip1
 and causes permanent arrest at G1 phase (Chen et al., 1998; Serrano et 
al., 1997). In addition, ROS accelerates telomere shortening (von Zglinicki, 
2002) or induces the formation of DNA damage foci (SDF), which initiates 
DDR and leads to senescence (Passos et al., 2010). Besides being exogenous 
triggers themselves, ROS also functions as intracellular signaling molecules. 
When cells are under cellular stress or oncogenes are overexpressed, p21
Cip1
 
induces mitochondrial dysfunction which leads to ROS production. These 
intracellular ROS maintains persistent DDR and causes permanent growth 
arrest (Passos et al., 2010).  
1.4.2.4 Oncogene-induced Senescence 
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Oncogenes are genes which turn normal cells into cancerous cells when they 
are either overexpressed or mutated together with other additional mutations. 
Many types of cells respond to oncogenes by cessation of cell growth 
(Campisi and d’Adda di Fagagna, 2007). This was first observed when a 
mutant Ras (H-Ras
G12V
) was introduced into normal human fibroblasts which 
subsequently induced phenotypic changes of cells that resembled non-
proliferative cells (Serrano et al., 1997). The process was later termed as 
oncogene-induced senescence (OIS). It is different from replicative 
senescence as it is not dependent on telomere attrition (Wei and Sedivy, 1999). 
The underlying mechanisms of OIS are complex. Oncogenes such as Ras and 
Myc are able to cause single or double strand breaks on DNA. In addition, 
oncogenes also increase intracellular ROS production which triggers S-phase 
specific DDR (Di Micco et al., 2006). This DDR signaling is activated via 
ATM kinase that activates p53 resulting in senescence or apoptosis when 
damage is too severe to repair (Campisi and d’Adda di Fagagna, 2007). 
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Figure 1.2 Causes and characteristics of cellular senescence. Cells respond 
to multiple stressors by undergoing senescence which exhibit altered 
behaviors such as cell-cycle arrest.  In addition, senescent cells are further 
characterized by altered gene expressions which resulted in altered protein 
expression, morphological changes and altered apoptotic response. 
 
 
1.5 Major Regulators involved in Cellular Senescence 
Two major proteins that mediate senescence are pRB and p53.  The pathways 
controlled by pRB or p53 are not completely independent of one another, but 
cross talk at various levels and together they induce and maintain cellular 
senescence in response to a variety of stimuli (Bringold and Serrano, 2000; 
Yap et al., 1999). 
 
Figure 1.3 Two major pathways of cellular senescence. Senescence signals 
usually trigger either the p16-pRB or the p53 tumor suppressor dependent 
pathways. However, these two pathways are not completely independent on 
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each other as they do cross-talk at multiple levels to induce irreversible cell 
cycle arrest.  
 
 
1.5.1 pRB  
The retinoblastoma protein (pRB), a tumor suppressor also known as “master 
regulator”, is a main regulator of G1-S phase in the cell cycle (Burkhart and 
Sage, 2008). Generally, pRB is dysfunctional in tumors, but it is required to be 
active to induce senescence.  
1.5.1.1  pRB and E2F in Senescence  
The most important function of pRB is to inhibit transcription of genes that are 
required for G1-S phase transition and DNA replication, both of which are 
mediated by transcription factor E2F. Rb binds and prevents E2F from 
activating its target genes (Chicas et al., 2010). Under normal conditions, 
mitogenic stimuli trigger the activation of numerous signaling cascades, such 
as the mitogen activated protein kinase (MAPK) pathway, which in turn 
induce the expression of various genes including cyclin D1 (Lavoie et al., 
1996).  When cyclin D1 is up-regulated, CDK4 (cyclin dependent kinase) and 
CDK6 phosphorylate and inactivate pRB. As a result, E2F is released from 
pRB-E2F complex and is able to transcribe its target genes. Under stress 







 specifically binds and inhibits cyclin D dependent 
kinases. As a result, pRB is active upon hypophosphorylation from CDKs and 
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inhibits E2F to transcribe downstream genes. Thus cells are arrested at G1 
phase (Lanigan et al., 2011).  
In addition, pRB also represses E2F-mediated transcription partially by 
recruiting proteins that are involved in post-translational modifications, 
including chromatin binding protein HP1, histone deacetylases (HDACs), 
DNA methyl transferases (DNMTs), chromatin remodeling factor Brg1 and 
histone methylation transferases (HMT) (Burkhart and Sage, 2008; Rayman et 
al., 2002; Nielsen et al., 2001). pRB-mediated chromatin modulation is 
important for senescence because it leads to formation of senescence-
associated heterochromatic foci (SAHF) at the E2F-dependent promoter which 
silences E2F target genes (Narita et al., 2003). 
1.5.2 p53 
p53 is another critical regulator involved in permanent cell growth arrest. 
Since it is one of the three proteins which I have studied in this project, more 
details are elaborated below.  
p53 was first identified in 1979 as an oncogene as it had the potential to 
promote tumor growth (Dippold et al., 1981). However, it was discovered ten 
years later that the initial p53 which was studied was a mutant form of p53 
(Finlay et al., 1989). Instead of being an oncogene, the wild type p53 was able 
to repress growth of transformed cells and tumors, suggesting it could behave 
as a tumor suppressor (Eliyahu et al., 1989; Baker et al., 1990). Subsequently, 
more studies revealed it played a vital role in almost all types of human 
cancers. Dysfunctional p53 or loss of p53 is observed in more than 50% of all 
cancer cases.   
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1.5.2.1 The Structure of p53 
p53 protein contains 393 amino acids (aa) with several domains, such as the 
N-terminus transactivation domain (1-42aa), a proline-rich region which has 
multiple copies of PXXP sequence (61-94aa), a DNA-binding domain (102-
292), tetramerization domain (324-355aa) and regulatory domain (363-393aa). 
In addition, p53 contains one nuclear localization signal sequence and three 
nuclear export signal sequences (Soussi and May, 1996).  
The N-terminus is important for p53 to recruit transcriptional machinery in 
order to transcribe downstream target genes (Lu and Levine, 1995). The 
proline-rich region plays a role in p53 mediated apoptosis (Sakamuro et al., 
1997). The central DNA-binding domain is responsible for sequence specific 
DNA binding and harbors the most mutations related to human cancers (El-
Deiry et al., 1992). Tetramerization is required for transactivation activity 
(Pietenpol et al., 1994) and the regulatory domain at the C-terminal undergoes 
post-translational modifications, such as phosphorylation and acetylation that 
activate p53 (Hupp and Lane, 1994).  
 
Figure 1.4 Schematic diagram of p53 structure. It has 393aa which consists 
of 4 domains, i.e. an N-terminal transactivation domain, a central DNA 
binding domain and C-terminal tetramerization and regulatory domains. N: N-
terminus; C: C-terminus; NLS: nuclear localization signal sequence; NES: 
nuclear export signal sequence. Numbers indicate amino acid residue numbers.  
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1.5.2.2 Physiological Functions of p53 
Being the “guardian of the genome” (Lane, 1992), p53 responds to a variety of 
stress-inducing signals and initiates various biological functions to prevent 
inappropriate cell proliferation (Vousden and Lu, 2002). When cells are 
exposed to DNA damaging agents such as ionizing radiation, 
chemotherapeutic or cytotoxic drugs, UV radiation, infectious virus, or when 
cells are under hypoxic conditions or express oncogenes, p53 is activated. This 
results in increased protein levels and activity which then leads cells to either 
apoptosis, cell cycle arrest, cellular senescence or DNA repair (Yee and 
Vousden, 2005; Riley et al., 2008; Green and Kroeme, 2009).  
1.5.2.2.1 p53 in Senescence 
p53 acts as a critical mediator for senescence caused by telomere shortening, 
DNA damage, ROS, oncogenic stress (Bond et al., 1994; Vaziri, 1997; 
Alimonti et al., 2010; Serrano et al., 1997).  
1.5.2.2.2 p53 mediated cellular senescence  
Various groups have investigated the underlying mechanisms on p53-induced 
senescence. Although the complete process is not fully understood, it is well 
documented that p53 is activated by several upstream regulators in response to 
different stresses. When cells are exposed to DNA damage, ataxia-
telangiectasia mutated (ATM) and ataxia-telangiectasia and Rad3-related 
(ATR) protein kinases are activated (Shiloh, 2003), which in turn activate 
checkpoint kinase1 and 2 (CHK1/2) that phosphorylate p53 so that p53 is 
stabilized and activated (Sancar et al., 2004). In addition, p53 is also induced 
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by increased expression of alternate-reading-frame (ARF) (p14ARF in human 
or p19ARF in mouse), a tumor suppressor gene that encoded by INK4a-ARF 
locus, under oncogenic stress. ARF activates p53 by inhibiting Mdm2-
mediated degradation (Weber et al., 1999).  
Once p53 is stabilized and activated, it is able to transcribe its downstream 
target genes. p21
Cip1
 is the most established downstream effector of p53. 
Together p53- p21
Cip1
 plays a crucial role in regulating cellular senescence. 
Studies have revealed that ectopic expression of either p53 or p21
Cip1
 induces 
cellular senescence in human cells (Wang et al., 1998; Brown et al., 1997). In 
addition, overexpression of p53 upstream genes, p14ARF, leads to senescence 
in human diploid fibroblasts (HDF) (Wei et al., 2001). Similarly, senescence 
is also observed in human glioblastoma cells when treated with Mdm2-p53 
interaction inhibitor, nutlin-3 (Villalonga-Planells et al., 2011). p53 induced 
senescence is p21
Cip1
 dependent as human fibroblasts lacking p21
Cip1
 were 
able to bypass cellular senescence (Brown et al., 1997).   
1.5.2.3  p53 in Replicative Senescence 
The very first link between p53 and senescence was from a study using SV40 
virus large T antigen. It demonstrated that T antigen led to longer lifespan of 
human fibroblasts in vitro upon binding and inhibiting both p53 and pRB 
(Gorman and Cristofalo. 1985). Later, studies confirmed p53 is important in 
replicative senescence as inactivation of p53 using anti-sense oligonucleotides 
increased cell lifespan; and inactivation of both p53 and pRB resulted in an 
even greater lifespan extension compared to inactivation of either p53 or pRB 
alone (Dimri and Campisi, 1941). In addition, microinjection of p53 
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antibodies rescued cells undergoing senescence (Gire and Wynford-Thomas, 
1998). These findings indicate that p53 is important in replicative senescence.  
1.5.2.4 p53 in Premature Senescence  
Genotoxic agents such as UV and ionizing radiation generate intracellular 
ROS, and accumulation of ROS leads to DNA damage which triggers p53-
mediated cellular senescence. Under sub-lethal level of H2O2 treatment, the 
platelet-derived growth factor ß (PDGFß) receptor is phosphorylated and ATM 
kinase activity is also enhanced. These two events lead to increased p53 
phosphorylation specifically at Ser15 that is responsible for p53 induction and 
transcriptional activation (Chen et al., 1998; Chen et al., 2003). As a result, 
p21
Cip1
 is activated which induces cells to undergo cellular senescence. 
Oncogenes, such as Ras and Runx1 trigger DNA damage response which 
induces p53 dependent premature senescence (Wotton et al., 2004). Moreover, 
p53 deficient cells are unable to undergo cellular senescence even in the 
presence of oncogenic Ras (Serrano et al., 1997).  
1.5.2.5  Regulation of p53  
As a major tumor suppressor, p53 level and activity are tightly regulated. 
Under normal conditions, wild type p53 is kept at a very low concentration 
and remains as inactive form (Levine, 1997). However, when cells are 
exposed to cellular stress or DNA damaging agents, p53 gets activated. Over 
the years, multiple positive and negative feedback loops have been identified 
to regulate both p53 expression and activity so that cells can respond 
accordingly under various conditions. For example, the stability of p53 is 
increased upon binding to SV40 T antigen (Tiemann et al., 1995) or WT1 
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(Maheswaran et al., 1995), whereas binding to E6 (Huibregtse et al., 1991) or 
Murine Double Minute-2 (Mdm2) (Kubbutat et al., 1997) leads to its 
degradation.  
1.5.2.6 Regulation of p53 by Mdm2 
A key negative regulator of p53 expression in cells is Mdm2 proto-
oncoprotein. It is an E3 ubiquitin ligase that binds to p53 to inhibit its 
transcriptional activity as well as its biological responses in unstressed cells. In 
addition, the interaction between these two proteins decreases p53 protein 
level as Mdm2 ubiquitinates p53 and exports it to the cytoplasm which then 
promotes a rapid proteosome dependent degradation of p53 (Kubbutat et al., 
1997; Freeman and Levine, 1998). 
Moreover, studies have shown that Mdm2 gene contains a p53 dependent 
promoter and it is transcriptionally regulated by p53. In this way, an 
autoregulatory feedback loop is established as p53 regulates Mdm2 gene at its 
transcription level and Mdm2 regulates p53 by altering p53 stability (Lahav et 
al., 2004). Multiple mechanisms abolish Mdm2-mediated degradation of p53, 
so that p53 is in its active form and is able to respond to various stimuli 
(Vousden and Lu, 2002). These mechanisms stabilize and activate p53 either 
by down-regulating Mdm2 or blocking p53 from interacting with Mdm2 thus 
preventing Mdm2-mediated degradation (Sionov and Haupt, 1999). In 
addition, p53 stability and activity can also be altered by post-translational 
modifications (PTM).  
1.5.2.7 Regulation of p53 by Post-Translational Modifications (PTM) 
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Under various genotoxic stresses, p53 stability and activity are tightly 
regulated by complex networks of post-translational modifications (Oren, 
1999), such as phosphorylation, acetylation, ubiquitination, sumoylation, 
neddylation, ADP-ribosylation, methylation and cytoplasmic sequestration 
(Bode and Dong, 2004; Vousden and Lu, 2002; Vogelstein, et al., 2000). 
Phosphorylation and acetylation are two main modifications that occur at both 
N and C-terminal on p53. Other than stabilizing p53 and increasing 
transcriptional activity of p53 (Appella and Anderson, 2001), they also prevent 
p53 from Mdm2-mediated degradation by inhibiting Mdm2-p53 interaction 
(Brooks and Gu, 2003). 
 
Figure 1.5 Schematic diagram of p53 domain structures with major post-
translational modifications. Examples of major post-translational 
modifications showing in the diagram include phosphorylation, acetylation, 
ubiquitination and methylation. TAD: transactivation domain. TET: 
tetramerisation domain. REG: regulatory domain.  
 
1.5.2.8 Phosphorylation of p53 
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Phosphorylation is one of the crucial modifications as it stabilizes p53 and 
enhances p53 sequence specific DNA binding (Hupp and Lane, 1994). So far, 
twenty serine and threonine sites on p53 have been identified that can be 
phosphorylated by DNA damage or genotoxic stress.  
Generally, phosphorylation occurs at the N-terminal and enhances the stability 
of p53 by preventing the association between p53 and Mdm2. For example, 
Ser15 in human p53 (Ser18 in mouse p53) is phosphorylated by ATM/ATR 
family kinases following DNA damage. Phosphorylation at this site inhibits 
the interaction between Mdm2 and p53 and also prevents p53 from nuclear 
export. In addition, studies suggested this phosphorylation site is a pre-
requisite for acetylation by CBP/p300 on p53. As a result, p53 is stabilized 
(Shieh et al., 1997; Zhang and Xiong, 2001; Lambert et al., 1998). Similarly, 
phosphorylation on Ser20 in human p53 (Ser23 in mouse p53) by Chk1 and 
Chk2 in response to ionizing radiation also dissociates p53 from Mdm2 which 
leads to p53 stability (Shieh et al., 2000; Hirao et al., 2000).Studies revealed 
that phosphorylation at Ser315 and Ser392 might lead to a conformational 
change of p53 which becomes more active for DNA binding (Hao et al., 1996; 
Wang and Prives, 1995). Very little is known regarding dephosphorylation on 
p53. Early studies reported that Ser376 and Thr55 underwent 
dephosphorylation following ionizing radiation, suggesting that 
dephosphorylation might also play a part to activate p53 functions (Waterman 
et al., 1998). 
1.5.2.9 Acetylation of p53 
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Acetylation of p53 is an important modification that plays a vital role in p53 
activation under various cellular stresses (Luo et al., 2000; Zhao et al., 2008) 
by enhancing p53 stabilization (Rodriguez et al., 2000) and its transcriptional 
activity (Barlev et al., 2001).   
p53 was the first non-histone substrate found to be acetylated by histone 
acetyltransferases (HATs) (Gu and Roeder, 1997). There are 13 lysine 
residues at C-terminal of p53, which are acetylated by histone 
acetyltransferases. Lys320 is acetylated by p300/CBP-associated factor 
(PCAF), whereas other sites are acetylated by CREB-binding protein 
(CBP)/p300 (Gu and Roeder, 1997; Liu et al., 1999).  
Recruitment of CBP/p300 to p53 induces a conformational change of p53 
(Kouzarides, 2000). As a result, DNA binding activity of p53 is increased in 
response to DNA damage in vitro (Gu and Roeder, 1997). However, this 
acetylation dependent p53 activity is cell type specific. For example, missense 
mutations of six C-terminal lysine residues to arginine (K6R) in mouse 
thymocytes and ES cells impaired p53-dependent gene expression in response 
of DNA damage, whereas mutations in MEFs do not alter p53 activity before 
and after DNA damage (Feng et al., 2005). Similarly, MEFs from knockin 
mice with p53-K7R gene show no differences in p53-mediated growth arrest 
(Krummel et al., 2005).  
Acetylation of p53 is also important for its stability. Recent studies have 
demonstrated that six lysine residues (370, 372, 373, 381, 382, 386) at C-
terminal of human p53 might be required for regulation of Mdm2-mediated 
degradation (Kubbutat et al., 1997). Mutation of these six lysine residues to 
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arginine (K6R) abrogates Mdm2-mediated ubiquitination of p53 (Rodriguez et 
al., 2000). However, the interaction between Mdm2 and p53 mutant is not 
affected by defective p53 ubiquitination. These findings suggest that 
acetylation and ubiquitination share the same lysine sites at C-terminal of p53. 
Upon DNA damage, acetylation at these lysine sites is able to prevent 
ubiquitination by Mdm2, which occurs on the same lysine sites. As a 
consequence, p53 is stabilized.  
Recently, acetyltransferases from MYST family such as TIP60 and hMOF 
were found to acetylate p53 at Lys120 within the DNA binding domain (Sykes 
et al., 2006). Acetylation at this site is important for activation of pro-
apoptotic genes and mutation of this lysine residue to arginine (K120R) 
inhibits p53-mediated apoptosis but not growth arrest (Tang et al., 2006).  
1.5.2.10 Deacetylation of p53 
Acetylation of p53 by PCAF or CBP/p300 is able to increase p53 stability and 
activity in cells, whereas the reverse process - deacetylation of p53 that is 
mediated by histone deacetylases (HDACs) inhibits these functions (Bode and 
Dong, 2004). Based on the conserved catalytic deacetylases domain, HDACs 
are grouped into four classes, namely Class I, II, III, IV, respectively 
(Grozinger and Schreiber, 2002). 
HDACs reduce stability of acetylated p53. In addition, they suppress p53 
transcriptional activity as well as biological functions such as growth arrest 
and apoptosis (Luo et al., 2000). The HDAC class I inhibitor, depsipeptide 
induces acetylation on lysine 373/382 on p53. As a consequence, p21
Cip1
 
expression increases (Zhao et al., 2006). Similarly, other class I HDAC 
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inhibitors TSA or sodium butyrate activates p53 by acetylation at lysine 320 
and lysine 373. Upon acetylation, p53 increases proapoptotic gene expression 
and apoptosis (Terui et al., 2003). 
Other than being deacetylated by HDAC1 (Luo et al., 2000), p53 can also be 
deacetylated by Sirt1, a class III deacetylase (Luo et al., 2001; Vaziri et al., 
2001).  Sirt1, a NAD
+
 dependent deacetylase, binds to p53 and deacetylates 
p53 specifically at Lys382 (Lys379 for mouse). This deacetylation by Sirt1 
alters transcriptional activity of p53 (Vaziri et al; 2001; Luo et al., 2001) and 
the ability of p53 to induce growth arrest as well as p53-mediated apoptosis is 
compromised (Luo et al., 2000). Interestingly, inhibiting Sirt1 activity using 
chemicals such as nicotinamide or sirtinol increases p53 acetylation, but does 
not affect cell survival in response of DNA damage in human mammary 
epithelial cells (Solomon et al., 2006). Since Sirt1 is a protein of interest in 
this project, it will be discussed in detail later. 
1.6 Mammalian Sirtuins 
Class III HDACs consists of seven isoforms (Sirt1-7) that are the mammalian 
homologues of yeast (Saccharomyces cerevisiae) Silent information regulator 
(SIR2). Structurally, they share a highly conserved sirtuin core domain (Frye, 
2000) but differ in N and C termini. In addition, they are involved in different 
biological functions due to their specific sub-cellular localizations, expression 
patterns as well as their substrates (Cen et al., 2011).  
Sirtuins act as transcriptional regulators in various cellular functions, such as 
cell cycle, senescence, metabolism, apoptosis and autophagy (Finkel et al., 
2009). Out of the seven members, we chose to study Sirt1 in this project as it 
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has been reported to interact with Sharp-1, and impact p53 activity and 
senescence.   
1.6.1 Sirt1 
Silent mating type information regulation 1 (Sirt1) was initially identified as a 
nuclear protein. Subsequently, studies showed that it could shuttle between 
nucleus and cytoplasm (Tanno et al., 2007). Early reports suggested Sirt1 
promoted longevity in mammals and was able to extend life-span upon caloric 
restriction (Cohen et al., 2004). As a consequence, studies on Sirt1 have been 
focused on the association with ageing as well as a variety of ageing related 
diseases, such as metabolic syndromes, neurodegeneration, cancer and 
immune diseases (Haigis and Sinclair, 2010; Saunders and Verdin, 2007).  
1.6.2 Sirt1 deacetylated targets  
Sirt1 deacetylates both histone and non-histone targets in a NAD
+
 dependent 
manner (Imai et al., 2000; Vaziri et al., 2001).  
1.6.2.1 Histone Targets 
Sirt1 deacetylates a variety of histones at specific lysine residues, such as 
H1K26, H3K9, H3K14, and H4K16 in vitro (Imai et al., 2000; Vaquero et al., 
2004) and preferentially deacetylates histone H4K16. Since acetylated H4K16 
is a chromatin mark related to euchromatin (Johnson et al., 1998), 
hypoacetylated K16 by Sirt1 might be a possible mark for gene silencing.  
1.6.2.2 Non-histone targets  
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Sirt1 is able to deacetylate a number of non-histone targets that can be 
categorized into five groups: (1) Transcription factors, such as p53 (Vaziri et 
al., 2001), FOXO proteins (Motta et al., 2004), MEF2s (Zhao et al., 2005). (2) 
Proteins involved in signaling pathways, such as SMAD7 (Kume et al., 2007), 
NFκB (Yeung et al., 2004). (3) Tumor suppressors, such as p73 (Dai et al., 
2007), PTEN (Ikenoue et al., 2008). (4) DNA repair proteins including Ku70 
(Jeong et al., 2007), XPA (Fan and Luo, 2010). (5) Nuclear hormone receptors, 
such as AR (Fu et al., 2006) and LXR (Li et al., 2007).  
1.6.3 Cellular Regulation of Sirt1 
Most of the early research works had focused on Sirt1 function, but how Sirt1 
is regulated was not well studied. In 2007, the first protein activator of Sirt1, 
AROS, was identified (Kim et al., 2007), since then more reports showed Sirt1 
is regulated at the transcriptional and post-translational level as well as by its 
subcellular localization. 
1.6.3.1 Regulation of Sirt1 at Transcriptional Level 
Sirt1 protein level alters when cells are exposed to various stresses, such as 
oxidative stress and nutrient deprivation. So far, several transcription factors 
are known to regulate Sirt1 expression under oxidative stress, namely, E2F1 
(Wang et al., 2006), HIC1 (Chen et al., 2005) and p53 (Nemoto et al., 2004). 
E2F1 binds directly at Sirt1 promoter to regulate basal Sirt1 expression. Under 
oxidative stress or DNA damage, E2F1 is phosphorylated by ATM which 
increases Sirt1 transcription (Wang et al., 2006). However, the enhanced level 
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of Sirt1 negatively regulates E2F1 transcriptional activity via Sirt1-mediated 
deacetylation (Wang et al., 2006).  
HIC1 (hypermethylated in cancer 1) is another transcription factor that 
regulates Sirt1 expression. In order to function as a transcriptional repressor, 
HIC1 recruits the co-repressor carboxy terminal of E1A-binding protein (CtBp) 
through a conserved GLDLSKK motif (Chen et al., 2005). CtBp functions as a 
redox sensor and its activity depends on NADH levels. When NADH level is 
high, it promotes both CtBp dimerization and interaction with HIC1 (Kumar et 
al., 2002; Zhang et al., 2007). In turn, HIC1 inhibits Sirt1 transcription by 
forming a transcriptional repression complex with Sirt1 through two binding 
sites on Sirt1 promoter (Chen et al., 2005). Therefore, under oxidative stress 
or caloric restriction, a change of cellular redox level is sensed by CtBp which 
alters its affinity with HIC1. As a result, Sirt1 expression level is up-regulated 
due to reduced recruitment of CtBp to HIC1 (Stankovic-Valentin et al., 2007).  
p53 also regulates Sirt1 transcription.  There are two p53 binding sites in the 
Sirt1 promoter which result in inhibition of Sirt1 expression under normal 
conditions (Nemoto et al., 2004). However, when there is nutrient deprivation, 
forkhead box O transcription factor FOXO3a is translocated from cytoplasm 
into nucleus which then interacts with p53 and inhibits its activity, resulting in 
stimulation of Sirt1 expression (Nemoto et al., 2004).   
1.6.3.2  Regulation of Sirt1 at Post-Transcriptional Level 
Sirt1 mRNA stability is tightly regulated. HuR, a RNA-binding protein that 
plays a critical role in cell cycle, senescence and cellular response, binds to 3’-
untranslated region (3’UTR) on Sirt1 mRNA to stabilize it thus leading to 
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increased Sirt1 protein. However, under oxidative stress condition, ChK2 is 
activated which phosphorylates HuR and causes a dissociation of Sirt1 mRNA 
from HuR, resulting in reduced Sirt1 expression (Abdelmohsen et al., 2007).   
Apart from HuR, recent findings also indicate that short non-coding RNAs 
such as microRNAs regulate target gene expression in a post-transcriptional 
manner. Both micro RNA 34a (miR-34a) and miR449a are transcriptional 
targets for p53 and E2F1, respectively. They are able to bind to the 3’ 
untranslated region of Sirt1 mRNA and inhibit Sirt1 expression (Yamakuchi et 
al., 2008; Lizȇ et al., 2010).  
1.6.3.3  Regulation of Sirt1 at Post-Translational Level 
Sirt1 enzyme activity is regulated by post-translational modifications in which 
sumoylation and phosphorylation are the two most important regulatory 
mechanisms.  
Sirt1 activity is enhanced by sumoylation that is mediated by a small 
ubiquitin-like modifier (SUMO-1) at lysine 734 (K734) (Yang et al., 2007). 
Similarly, desumoylation is mediated by a family of specific isopeptidase 
known as SENP desumoylases (Yeh et al., 2000). Both sumoylation and 
desumoylation regulate Sirt1 enzymatic activity in the presence or absence of 
cellular stress (Yang et al., 2007). Under normal conditions, SUMO1 binds at 
K734 on Sirt1 leading to an increased deacetylase activity. However, in the 
presence of genotoxic stress, such as UV radiation and H2O2, Sirt1 is 
associated with SENP1 and undergoes desumoylation leading to inhibition of 
its deacetylase activity (Yang et al., 2007). As a consequence, Sirt1 substrate 
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such as p53 is acetylated and mediates response to genotoxic stress (Kong et 
al., 2009).  
Sirt1 can also be phosphorylated by C-Jun N-ternimal kinase2 (JNK2) (Ford et 
al., 2008) and casein kinase 2(CK2) (Zschoernig and Mahlknecht, 2009). 
JNK2 either directly or indirectly interacts with Sirt1 and phosphorylates it at 
Ser27. Knockdown of JNK2 by siRNA affects Sirt1 protein stability as the 
half life of Sirt1 protein is significantly reduced. On the other hand, CK2, a 
key regulator of cell cycle control, DNA repair, circadian rhythm (North and 
Verdin, 2007), phosphorylates Sirt1 at four conserved serine residues under 
stress conditions. CK2 interacts and phosphorylates Sirt1 when cells are 
exposed to DNA damage agents such as ionizing radiation (IR). This 
phosphorylation increases not only the binding affinity between Sirt1 and its 
substrate but also deacetylase activity. As a result, a better survival of cells is 
observed as phosphorylated Sirt1 causes increased p53 deacetylation due to 
enhanced binding after DNA damage (Zschoernig and Mahlknecht, 2009).  
1.6.3.4  Regulation of Sirt1 by protein-protein interaction 
Two Sirt1-binding proteins, namely, active regulator of Sirt1 (AROS) and 
deleted in breast cancer 1 (DBC1), have been discovered which regulate Sirt1 
activity through protein-protein interactions under cellular stress conditions 
(Kim et al., 2007; Zhao et al., 2008; Kim et al., 2008).  
AROS specifically binds to N-terminus of Sirt1 but not other sirtuins and leads 
to a conformational change that results in an enhanced Sirt1 activity. Since 
AROS acts as a positive regulator of Sirt1, it stimulates Sirt1 mediated 
deacetylation of p53 in response to DNA damage. As a result, p53-mediated 
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transcription activation as well as biological functions such as growth arrest 
are inhibited (Kim et al., 2007). On the other hand, DBC1, another protein that 
also specifically binds to Sirt1 but not other members from Sirtuin family, 
negatively regulates Sirt1 activity. DBC1 is phosphorylated by ATM under 
genotoxic stress, and this phosphorylation creates a second binding site for 
Sirt1 which makes the association between DBC1 and Sirt1 even stronger. The 
suppression of Sirt1 activity mediated by DBC1 resulted in increased p53 
acetylation in response to cellular stress (Yuan et al., 2012).  
1.6.4 Sirt1 Activators and Inhibitors  
1.6.4.1 Sirt1 Activators 
1.6.4.1.1 Resveratrol 
Resveratrol (RSV), a polyphenol found in the skin and seeds of grapes, is the 
first compound known to stimulate Sirt1 (Howitz et al., 2003). Though it does 
not regulate Sirt1 directly, RSV is able to activate the calcium/calmodulin-
dependent protein kinase II (CaMKII) which leads to phosphorylation on 
cAMP-Epac1-AMP-activated kinase (AMPK). As a result, NAD
+
 levels 
increase in the cell, which causes the activation of Sirt1 deacetylation activity 
(Park et al., 2012). Moreover, AMPK activation induces dissociation between 
Sirt1 and its inhibitor- DBC1, which makes Sirt1 even more active (Nin et al., 
2012).  
1.6.4.2 Sirt1 Inhibitors 
1.6.4.2.1 Sirtinol 
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Sirtinol, one of the well-established Sirt1 inhibitors, is the first cell-permeable 
inhibitor discovered via cell-based screening (Grozinger et al., 2001). It 
inhibits Sirt1deacetylation activity resulting in p53 acetylation. Hence, p53 is 
able to carry out its biological functions to respond to various genotoxic 
stimuli (Vaziri et al., 2001).  
1.6.4.2.2 Nicotinamide (NAM) 
Sirt1 is an NAD
+
 dependent deacetylase and its deacetylation reaction 
produces both O-acetyl-ADP-ribose and nicotinamide. A study has 
demonstrated that nicotinamide strongly abolishes silencing in yeast and it is 
also able to inhibit both Sir2 and Sirt1 activities via non-competitive inhibition 
by binding to a conserved pocket near to NAD
+
. Hence, it blocks NAD
+
 
hydrolysis (Bitterman et al., 2002). 
1.6.5 Crosstalk between Sirt1 and ROS 
Evidence from Sadoshima’s group has shown that there is a crosstalk between 
Sirt1 and oxidative stress in mouse cardiac muscle. They demonstrated that 
overexpression of Sirt1 was able to induce catalase expression which could 
protect cells against oxidative stress (Alcendor et al., 2007). In addition, Sirt1 
is able to deacetylate FOXO3a, FOXO4 (Brunet et al., 2004; Van der Horst et 
al., 2004), and FOXO1. Upon deacetylation, FOXO factors stimulate 
expression of antioxidants including catalase, superoxide dismutase through 
an auto feedback loop that also positively regulates Sirt1 expression (Xiong et 
al., 2011). Therefore, Sirt1 acts as an intracellular inhibitor for oxidative stress 
by activating FOXOs that actively transcribe pro-survival target genes to 
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prevent any potential damages caused by oxidative stress (Rajendran et al., 
2011).   
1.6.6 Sirt1-mediated deacetylation of p53 and Senescence 
Acetylation is essential for p53 stabilization, and several studies have shown 
that Sirt1-mediated deacetylation of lysine 382 (K379 in mouse) destabilizes 
p53 (Langley et al., 2002; Luo et al., 2001; Vaziri et al., 2001), possibly by 
promoting Mdm2-mediated ubiquitination and proteosomal degradation as 
well as abrogating p53 DNA binding ability (Luo et al., 2004). Moreover, p53 
acetylation is important for its transcriptional activity, which is attenuated by 
Sirt1-mediated deacetylation (Luo et al., 2001). On the contrary, p53 
acetylation increases when cells are treated with siRNA against Sirt1 (Ford et 
al., 2005). In addition, Sirt1 dominant negative mutant increases p53 
dependent transcriptional activity in the presence and absence of DNA damage 
(Lain et al., 2008). 
Various groups have shown that Sirt1 might protect cells against p53-mediated 
cellular senescence. Langley et al have demonstrated that Sirt1 is recruited to 
nuclear bodies and directly associates with both promyelocytic leukemia 
protein (PML) IV and p53 upon PML IV up-regulation or oncogenic Ras 
expression. This recruitment of Sirt1 inhibits both p53-mediated 
transactivation as well as rescued PML-induced cellular senescence by 
inhibiting PML-mediated p53 acetylation (Langley et al., 2002).  
As p53 acetylation is increased with senescence (Pearson et al., 2000), it 
would be expected that overexpression of Sirt1 could block premature 
senescence through deacetylation of p53 (Langley et al., 2002). Indeed, human 
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epithelial cells display premature senescence like phenotypes due to decreased 
Sirt1 level (Ota et al., 2007). Moreover, the Sirt1 inhibitor, sirtinol, is able to 
induce senescence-like growth arrest in both human breast and lung cancers 
by attenuating Ras-MAPK signaling pathway (Ota et al., 2006). On the 
contrary, overexpression of Sirt1 prevents human fibroblast cells from 
undergoing senescence by directly deacetylating both p53 and pRB or possibly 
by activating ERK/S6K1 signaling pathway that leads to reduced p16
INK4a
 
expression (Ota et al., 2007; Huang et al., 2008).  
Apart from regulating Sirt1 expression levels, changing Sirt1 deacetylase 
activity by modulating NAD
+
 biosynthesis in cells could also have an impact 
on cellular senescence. Both NAD
+
 and nicotinamide are two important 
regulators that affect Sirt1 deacetylase activity, and nicotinamide 
phosphoribosyl-transferase (Nampt) is known to increase cellular NAD
+
 level 
and results in an enhanced Sirt1 activity. Both replicative senescence and drug 
induced premature senescence in human vascular smooth muscle cells display 
reduced Nampt activity. When Nampt is overexpressed in cells, it increases 
Sirt1 activity and prevents p53-dependent senescence (van der Veer et al., 
2007).  
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Figure 1.6 Sirt1 mediated deacetylation of p53 under stressed condition. 
Cellular stresses such as DNA damage or oxidation causes hyperacetylation of 
p53 on K382 (in human) by acetyl transferase CBP/p300. Acetylated p53 is 
more stable and active which then triggers various functions including cell-
cycle arrest, senescence or apoptosis. Sirt1 prevents p53 regulated functions 
through deacetylation of K382 on p53. (Adapted from Trends in Cell Biology. 
2002, 12: 404-406). 
 
Even though there are abundant findings regarding the mechanisms underlying 
cellular senescence, the complex physiological phenomenon is still not 
completely understood. Recently, Chen’s group has shown that overexpression 
of Dec1 (differentiated embryochondrocyte expressed-1) leads to p53-
dependent premature senescence (Qian et al., 2008). In addition, 
overexpression of Dec1 is observed in precursor lesions of esophageal 
squamous cell carcinoma (ESCC) and this correlates to better survival in 
patients with ESCC by inducing cellular senescence of cancerous cells (Xu et 
al., 2012). DNA microarray analysis also identified that Dec1 could be used as 
the de novo markers for oncogene-induced cellular senescence (Collado and 
Serrano, 2006). Dec1 (Stra13 in mouse) belongs to Stra13/Dec subfamily of 
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basic helix-loop-helix transcription factors which consists of another member: 
Sharp-1 (Sun et al., 2007). Our lab previously demonstrated that Sharp-1, a 
transcription repressor, plays a key role in cellular differentiation (Azmi et al., 
2003; Azmi et al., 2004; Gulbagci et al., 2009) and it regulates cellular growth 
arrest and apoptosis (Liu et al., 2010). Moreover, Sirt1 interacts with Sharp-1 
(Fujimoto et al., 2007) though the significance remains unknown.  
1.7 Perspectives and Aims of Study 
Several recent studies have suggested that Sharp-1 may be a potential tumor 
suppressor (Sato et al., 2008; Falvella et al., 2008; Li et al., 2010; Liu et al., 
2010; Wu et al., 2011; Montagner et al., 2012). Our lab has shown that 
overexpression of Sharp-1 induces cell cycle arrest in fibroblast cells and also 
renders cells’ resistance to apoptosis. Since cell cycle arrest and reduced 
apoptosis are apparent in senescent cells, in this project we examined whether 
Sharp-1 mediated growth arrest leads to cellular senescence. Moreover, since 
previous studies have established that Sharp-1 can interact with Sirt1, we have 
also explored the regulatory connection between Sharp-1 and Sirt1 in 
senescence.  
In the first part of the study, I demonstrate that overexpression of Sharp-1 is 
able to induce growth arrest and premature senescence in fibroblast cells. This 
is accompanied by increased intracellular ROS production, specifically H2O2 
and elevated p53 levels. Since Sirt1 has an opposite impact i.e it inhibits 
cellular senescence by regulating catalase expression which scavengers H2O2, 
we hypothesized that Sirt1 may antagonize Sharp-1 induced senescence. We 
show that increasing Sirt1 activity using resveratrol or increasing its 
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expression in Sharp-1 overexpressing cells inhibits Sharp-1 mediated 
senescence concomitant with deacetylation of p53 at lysine 379 (K379). In 
addition, co-immunoprecipitation and GST pull-down assays demonstrate that 
Sharp-1 directly interacts with Sirt1 and this association weakens upon cellular 
stress. These findings suggest that the antagonism between Sharp-1 and Sirt1 
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2. Materials and Methods 
2.1  Cell Culture 
NIH3T3 and doxycycline inducible Sharp-1 overexpressing NIH3T3 cells (Liu 
et al., 2010) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma Aldrich, St. Louis, United States) supplemented with 3.7 g/L sodium 
bicarbonate (Sigma Aldrich, St. Louis, United States), 10% bovine serum (BS) 
(Gibco, Langley, United States) and 1x penicillin-streptomycin. MEF (mouse 
embryonic fibroblasts) cells (kindly provided by Ms. Sumita Sethi) were 
cultured in DMEM supplemented with 3.7 g/L sodium bicarbonate, 10% FBS 
(Gibco, Langley, United States), 1% Minimal Essential Medium (MEM) non-
essential amino acids (Gibco, Langley, United States), 1% gentamicin (Sigma 
Aldrich, St. Louis, United States) and 0.02% 2-mercaptoethanol (Sigma 
Aldrich, St. Louis, United States).  
All cells were cultured in a humidified incubator which is supplied with 5% 
CO2 at 37
o
C (Sanyo CO2 Incubator, MCO-19A1C, Japan).  
2.2  DNA Constructs 
Plasmid pCDNA-FLAG-Sirt1 was kindly provided by Dr. Martin J. Walsh 
(Mt Sinai School of Medicine, New York, NY10029). Plasmid pCMV-p53 
was kindly provided by Dr. Bert Vogelstein (Howard Hughes Medical 
Institute, Chevy Chase, MD 20815). Myc-Sharp-1 (1-410aa) and all mutant 
constructs [Myc-Sharp-1 bHLH (1-112aa), Myc-Sharp-1 ΔO (368aa) and 
Myc-Sharp-1ΔN (1-265 aa)] were cloned into pCS2 vector have been 
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previously described (Gulbagci et al., 2009; Ling et al., 2012). GST-Sharp-1 
construct has also been previously described (Azmi et al., 2003).  
2.3  Transformation  
50-100 ng of plasmid was added and mixed thoroughly with 25-50 µl of 
DH5α competent E.coli cells (Invitrogen, Carlsbad, United States) and 
incubated on ice for 30 minutes. After incubation, cells were subjected to heat-
shock in 42
o
C for 30 seconds and immediately cooled on ice for 2 minutes. 
500 µl of pre-warmed Luria-Bertani (LB) broth (Sigma Aldrich, St. Louis, 
United States) was added to the cells and incubated at 37
o
C for 1 hour with 
shaking at 250 rpm. After incubation, cells in the LB broth were pelleted down 
at 13,000 rpm for a minute.  For positive selection of colonies, 100-200 µl of 
transformation mixtures were plated on LB agar plates containing ampicillin 
(100 μg/mL) and incubated overnight at 37˚C.  
2.4    Plasmid DNA Extraction from Escherichia coli by Midi Prep 
Single colony was inoculated into 2 ml LB broth containing ampicillin and 
grown at 37
o
C for 8 hours with shaking at 250 rpm. The mini-culture was 
scaled up into 300 ml LB broth containing ampicillin and grown at 37
o
C 
overnight with shaking at the same rpm.  
After overnight incubation, bacterial culture was spun down at 5000 rpm for 5 
minutes at 4
o
C and plasmid DNA extraction was carried out using Qiagen 
Plasmid Midi Kit (Qiagen, Venlo, United States) following manufacturer’s 
instruction. Briefly, bacterial pellet was resuspended completely with 4 ml of 
P1 buffer (with RNaseA added) and lysed with 4 ml of P2 buffer. After 
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incubating at room temperature for 5 minutes, pre-chilled P3 buffer was added 
to the lysate, mixed thoroughly and incubated on ice for 15 minutes.  
The mixture was spun down at 20,000 rpm for 45 minutes at 4
o
C and 
supernatant was collected and filtered through the equilibrated Qiagen midi 
column. Upon washing with buffer QC twice to remove traces of contaminants, 
DNA was eluted with buffer QF and precipitated with isopropanol. The DNA 
pellet was finally washed with 70% ethanol and centrifuged at 14000 rpm for 
10 minutes before being redissolved in TE buffer (10 mM Tris pH8, 1 mM 
EDTA). DNA concentration was quantified using Nanodrop 
spectrophotometer (NanoDrop-1000, Thermo Scientific) and stored in -20
o
C 
for future usage. 
 
2.5    Transient Transfection 
2.5.1  Transient Transfection for Protein Overexpression  
One day prior to transfection, appropriate cells were plated into various sizes 
of cell culture plates. Desired plasmids were transfected into cells using 
Lipofectamine and Plus reagent (Invitrogen, Carlsbad, United States) 
according to the manufacturer’s instructions.  
Briefly, for 10 cm-diameter cell culture plates, 4 µg of plasmid DNA was 
diluted into 300 µl of basal DMEM which was then added with 15 µl of Plus 
reagent. After incubating for 15 minutes at room temperature, 300 µl of 
DMEM with 20 µl of Lipofectamin reagent were added into the incubated 
mixture; mixed and incubated for another 15 minutes at room temperature. 
The transfection mixture was added drop-wise into cells cultured in serum free 
medium. Four hours after incubation, serum free medium was changed to 
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complete medium and transfected cells were cultured for desired period of 
time in 37
o
C incubator.  
 
2.5.2  Transient Transfection for siRNA mediated Knockdown 
Appropriate densities of cells were seeded in the cell culture plates one day 
before transfection. On the actual day of transfection, cells in 10 cm-culture 
plate were transfected either with total 500 ρmol of control scrambled siRNA 
(Dharmacon; on-target plus control pool; non-targeting pool) or 500 ρmol of 
siRNA specific for Sharp-1 (Qiagen, GeneSolution siRNA, Venlo, United 
States), Sirt1 or p53 (Dharmacon; on-target plus smart pool) using 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, United States) according to 
manufacturer’s instruction. Generally, 500 ρmol of siRNA in total was added 
into 100 µl of basal DMEM which was then mixed with 43 µl of 
Lipofactamine RNAiMAX in 100 µl of basal DMEM and incubated for15 
minutes at room temperature. The transfection mixture was added to the cells 
cultured in complete medium in a drop-wise manner and incubated at 37
o
C for 
desired period of time. 48 or 72 hours after transfection, cells were either 
harvested to check for knockdown efficiency using anti-Sirt1, anti-p53 
antibody or plated for future experiments. Sequences for mouse siSharp-1, 
mouse siSirt1 as well as mouse sip53 are shown in Table II, Table III and 
Table IV, respectively.  
2.6  Treatment of Cells with Chemicals  
2.6.1  Sirt1 Activator: Resveratrol 
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Resveratrol, a polyphenol found in red wine, is a well known Sirt1 activator 
(Howitz et al., 2003, Borra et al., 2005). In order to increase endogenous Sirt1 
activity, various concentrations of resveratrol (Sigma Aldrich, St. Louis, 
United States) from 2.5 µM to 25 µM were tested in NIH3T3 cells. Cells were 
collected and analysed by western blot.  Upon analysis, 2.5 µM of resveratrol 
generated the optimal result which was used for the subsequent experiments.  
NIH3T3 cells were either treated with 2.5 µM of resveratrol (dissolved in 
ethanol) for actual experiment or treated with same volume of ethanol as 
negative controls.  24 hours after treatment, cells were harvested for further 
analysis.  
2.6.2  Sirt1 Inhibitor: Sirtinol 
Sirtinol, a small molecule that inhibits only Sirtuin activity but not HDAC 
activity was used in this project to inactivate endogenous Sirt1 activity 
(Grozinger et al., 2001). Different sirtinol (Sigma Aldrich, St. Louis, United 
States) concentrations ranging from 5 µM to 50 µM were tested in NIH3T3 
cells. Cells were harvested and analysed by western blot. Based on the result, 
25 µM of sirtinol was chosen for subsequent experiments and control cells 
were treated with equal amount of DMSO.   
2.7  Treatment of Cells with Genotoxic Agents 
2.7.1  Cisplatin 
Cisplatin or Cis-diamminedichloroplatinum (CDDP) is a DNA damaging 
agent which is widely used as anti-cancer drug on solid tumors (Jordan and 
Carmo-Fonseca, 2000) as it is able to disrupt transcription or DNA replication 
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upon binding to DNA which eventually leads to apoptosis (Florea and 
Büsselberg, 2011). Based on previous study, 20 µM of cisplatin (Sigma 
Aldrich, St. Louis, United States) was used to treat NIH3T3, doxycycline 
inducible Sharp-1 expressing NIH3T3 cells and MEFs (Liu et al., 2010). 24 
hours after treatment, cells were collected, and lysed for immunoblotting.  
2.7.2    Etoposide 
Etoposide is a topoisomerase II inhibitor which is usually used as an anti-
neoplastic drug to induce DNA damage and apoptosis (Mizumoto et al., 1994). 
For all the experiments performed in this study, 20 µM of etoposide (Sigma 
Aldrich, St. Louis, United States) was selected (Liu et al., 2010) and control 
cells were treated with equal amount of DMSO.   
2.7.3    Hydrogen Peroxide 
Hydrogen peroxide (H2O2), one of the reactive oxygen species (ROS), is able 
to induce topoisomerase I-mediated DNA damage regardless whether they are 
introduced to the cells exogenously or produced as intracellular signaling 
molecule by cells themselves under stress conditions (Daroui et al., 2003; 
Gough and Cotter., 2011). A range of H2O2 (Merck Millipore, Billerica, 
United States) concentrations from 5 µM to 150 µM were tested in NIH3T3 
cell line with various exposure durations. Cells were harvested and lysates 
were checked by western blot for the optimal concentration. In this project, 50 
µM of H2O2 was chosen to induce moderate DNA damage when cells were 
exposed to it for 1 hour. In addition, cells treated with 150 µM of H2O2 for 20-
30 minutes were used as a positive control for intracellular ROS production.  
2.8  Western Blotting 
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At various desired time points, cells were trypsinized, harvested and lysed 
with radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM NaCl, 50 
mM Tris-HCl, pH8 (1
st
 Base, Singapore), 1mM EDTA (Sigma Aldrich, St. 
Louis, United States), 1% Triton X-100 (USB corporation, Affymetrix, 
Cleveland, United States), 0.05% SDS, 0.1% sodium deoxycholate (Sigma 
Aldrich, St. Louis, United States) and 1X  protease inhibitor (Roche, 
Indianapolis, United States). Lysis was carried out for 30 minutes at 4
o
C on a 
rotator. Cell debris was removed upon centrifugation at 14000 rpm for 15 
minutes at 4
o
C; supernatant was collected for future usage.  
Protein concentrations were measured using Bradford protein assay (Bio-Rad, 
Hercules, United States) and the absorbance was measured by 
spectrophotometer (Bio-Tek Instuments, Inc, Winooski, United States) at 
wavelength of 595 nm.  
Whole cell lysates were denatured by heating at 95
o
C for 6 minutes before 
loaded with 1x loading dye into SDS-PAGE gel (8% or 10%).  Proteins were 
separated by electrophoresis which were then transferred onto a nitrocellulose 
membrane (AmershamHybond ECL, GE Healthcare, Little Chalfont, United 
Kingdom) for at least 90 minutes. 
The nitrocellulose membrane was later blocked with 5% w/v skimmed milk in 
1X PBST (1X PBS with 0.1% Tween-20) for 1 hour at room temperature and 
then incubated with specific primary antibodies for either 1 hour at room 
temperature or overnight at 4
o
C. The membrane was washed with 1X PBST 
thrice to remove any unbound primary antibody and then incubated with horse 
radish peroxidase (HRP) conjugated secondary antibody at room temperature 
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for 1 hour. Proteins of interest on the blots were detected using ECL western 
blotting detection reagents (Amersham Biosciences GE Healthcare, United 
Kingdom).  
2.9  Primary and Secondary Antibodies 
2.9.1  Primary Antibodies 
Anti-FLAG (Sigma Aldrich, St. Louis, United States, 1:1000); anti-Myc 
(Sigma Aldrich, St. Louis, United States, 1:1000); anti-ß-actin (Sigma Aldrich, 
St. Louis, United States, 1:10000); anti-Sirt1 (Millipore, Billerica, United 
States, 1:10000); anti-p53 (Santa Cruz Biotechnology, Inc. Dallas, United 
States, 1:500); anti-p53 Lys379 (Cell Signaling, Danvers,  United States, 
1:500); anti-Dec2 (Santa Cruz Biotechnology, Inc. Dallas, United States, 
1:500).  
2.9.2  Secondary Antibodies 
Goat-anti-rabbit IgG (Sigma Aldrich, St. Louis, United States, 1:5000) and 
goat-anti-mouse IgG (Sigma Aldrich, St. Louis, United States, 1:5000).  
2.10  Co-Immunoprecipitation (Co-IP) Assay  
20 µl of anti-Myc or anti-FLAG agarose beads (Sigma Aldrich, St. Louis, 
United States) were washed twice with 1X PBS and added with 500 µg to 
1000 µg of cell lysates diluted in 500 µl of RIPA lysis buffer with 1X protease 
inhibitor. After overnight incubation at 4
o
C on a rotator, beads were washed 4 
times with RIPA lysis buffer at 4
o
C for 5 minutes each time. Supernatant was 
decanted carefully without disturbing the beads after centrifugation at 10000 
rcf for 30 seconds at each round of washing. To denature the proteins of 
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interest, beads in 3x loading dye were heated at 95
o
C for 6 minutes before 
loading for SDS-PAGE gel and analyzed by western blot.   
2.11  Immunofluorescence Assay (IF) 
NIH3T3 cells transfected with either Myc-Sharp-1 or FLAG-Sirt1 alone or 
both plasmids were cultured on coverslips (Thermonax, Thermo Scientific, 
West Palm Beach, United States). 24 hours after transfection, cells on the 
coverslips were gently washed thrice with 1X PBS and fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. Fixed cells were 
washed with 1X PBS for three times and then permeabilized with 0.5% Triton 
X-100 in 1X PBS for 10 minutes at room temperature. After rinsing the 
coverslips with 1X PBS, cells were incubated in blocking buffer (3% BSA) for 
an hour.  
Subsequently, cells on the coverslips were incubated with primary antibodies 
mouse-anti-Myc (Sigma Aldrich, St. Louis, United States, 1:250) or rabbit-
anti-Sirt1 (Millipore, Billerica, United States, 1:250) for 1 hour, respectively. 
Upon washing with 1X PBS for three times, the coverslips were incubated 
with Alexa Fluor 488 coupled with goat anti-mouse or goat anti-rabbit IgG 
secondary antibody (Molecular Probes, Grand Island, United States, 1:250) for 
1 hour.  
Coverslips were washed with 1X PBS for 3 times and mounted with 2µl DAPI 
(Vector Laboratories, Burlingame, United States) in dark for 2 minutes. The 
immunofluorescence images were captured using fluorescent microscope 
(Nikon Eclipse TE 2000-U, Japan) with 10X, 20X or 40X objective lens and 
analysed by Metamorph software version 7.0r3.   
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2. 12  Glutathione S-Transferase (GST) Pull-Down Assay  
GST-Sharp-1 and GST expressing plasmids were transformed in Escherichia 
coli BL21 cells. Single colony was picked and cultured overnight in 2 ml 
Luria Bertani (LB) broth with ampicillin at 37
o
C. Next day, 1 ml of overnight 
culture was transferred into 100 ml of LB broth with ampicillin and grew at 
30
o
C. 0.5 mM IPTG was added for induction when OD600 of the culture 
reached 0.8-1.0. After inducing for 3 hours, bacterial cells were harvested by 
centrifuging at 5000 rpm for 5 minutes. Cell pellets were resuspended with 10 
ml PBS solution (1% Triton X-100, 0.1 mM Dithiothreitol (DTT), complete 
protease inhibitor cocktail (Roche, Indianapolis, United States)).  
The resuspended bacterial pellet was subjected to sonication (cycle on 5 
seconds/ off 5 seconds, 6 cycles with amplitude at 40) and incubated in ice for 
30 minutes. Sonicated cells were spun down at 10000 rpm for 10 minutes at 
4
o
C; supernatant was collected and incubated with glutathione sepharose 4B 
beads on a shaker for 30 minutes at 4
o
C, then centrifuged at 2500 rpm for 2 
minutes at 4
o
C. After decanting the supernatant, the beads were washed with 
PBS solution and resuspended in the same solution with protease inhibitor to 
make a 50% slurry.   
GST-Sharp-1 and GST proteins were resolved by SDS-PAGE and quantified 
by coomassie blue staining. In vitro translated protein was prepared using 
TNT-coupled reticulocyte lysate system (Promega, Madison, United States) 
according to manufacturer’s protocol. 15 µl of in vitro translated FLAG-Sirt1 
was then incubated with 10 µg GST or GST-Sharp-1 fusion protein in 200 µl 
of binding buffer (50 mM Tris-HCl pH8.0, 100 mM NaCl, 0.3 mM DTT, 10 
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mM MgCl2, 0.1% NP-40, 10% glycerol, protease inhibitor cocktail) by 
rotating at 4
o
C for 2 hours.  
After incubation, the beads were washed thoroughly 4 times with binding 
buffer without protease inhibitor and resuspended in 20 µl of SDS-PAGE 
loading buffer. Samples were heated at 95
o
C for 6 minutes and separated by 
SDS-PAGE gel and analyzed by western blot. To detect direct binding 
between GST-Sharp-1 and FLAG-Sirt1, anti-FLAG antibody (Sigma Aldrich, 
St. Louis, United States, 1:1000) was used as primary antibody and 
horseradish-peroxidase conjugated anti-mouse IgG was used as secondary 
antibody (Sigma Aldrich, St. Louis, United States, 1:5000). 
2.13    Senescence Assay 
Cells were seeded in 6-well plates at density of 3.5 x 10
3
 per well and cultured 
for 7 days with changing of medium on every alternate day. Senescent cells 
were identified using Senescence Cells Histochemical Staining Kit (Sigma 
Aldrich, St. Louis, United States) by following manufacturer’s instructions. 
Briefly, cells were washed with 1X PBS twice and fixed with 1X fixation 
buffer and incubated at room temperature for 6 minutes. Cells were rinsed 3 
times with 1X PBS before incubating with staining mixture at 37
o
C without 
CO2 for 24 hours and visualized using light microscopy with 10X 
magnification (Olympus, CKX41, Japan).  
Quantification of senescence-associated (SA)-ß-gal positive staining cells was 
done by counting at least 300 cells from 5 separated fields and percentage of 
the positively stained blue cells was calculated as following: number of blue 
cells/ number of total cells x 100%.  
- 52 - 
 
2.14    Flow Cytometric Analysis of Intracellular ROS Production 
Intracellular ROS production was determined using flow cytometric method. 
Inducible Sharp-1 expressing NIH3T3 cells were induced with or without 
doxycycline (2 µg/ml) for 24 hours. In addition, 5 mM of N-acetylcysteine 
(NAC) was added into the induced NIH3T3 for 24 hours. Uninduced NIH3T3 
cells were treated with 150 µM of H2O2 for 15 minutes which served as a 
positive control for ROS production. Cells were collected and washed with 1X 
PBS in order to move any traces of medium. Cells were incubated with 5 mM 
of 5- (and-6- ) –chloromethyl-20, 70-dichlorofluorescin diacetate (CM-
H2DCFDA) (Molecular Probes, Eugene, OR, USA), a redox-sensitive dye that 
is used as a general indicator for ROS in cells, at 37
o
C for 15 minutes. To stop 
the staining reaction, 1ml of 1X PBS was added into the dye. Cells were 
analyzed by flow cytometry using BD Coulter flow cytometer with an 
excitation wavelength at 488 nm. Data were analyzed using Summit 4.3 
software with at least 10000 events counted.  
2.15  RNA Extraction and Purification 
Total mRNA was extracted using TRIzol (Invitrogen, Carlsbad, United States) 
according to manufacturer’s instructions. Briefly, cells cultured in 10 cm plate 
were harvested and mixed extensively with 1ml of TRIzol. After incubating at 
room temperature for 5 minutes, 0.2 ml of choloroform was added into each 
sample and mixed vigorously for 15 seconds before incubating at room 
temperature for 2-3 minutes. Samples were then centrifuged at 12,000 g at 4
o
C 
for 15 minutes which then separated into two phases. The aqueous phase was 
transferred into a new tube and RNA was precipitated by mixing with 0.5ml of 
- 53 - 
 
isopropanol and incubated at room temperature for 10 minutes before 
centrifuging at 12,000 g for 10 minutes at 4
o
C. Supernatant was then removed 
after spinning, and the RNA pellet was washed with 1ml of 75% ethanol and 
spun down at 7500 g for 5 minutes at 4
o
C. RNA pellet was air dried and 
resuspended in DEPC water which then incubated in a water bath at 55
o
C for 
15 minutes before stored at -20
o
C for further usage.  
2.16  Quantitative Real-Time Polymerase Chain Reaction (Q-PCR) 
RNA was reverse transcribed into cDNA using iScript TM Advanced cDNA 
Synthesis kit following manufacturer’s protocol (Bio-rad, Hercules, United 
States).cDNA was amplified using Lightcycler 480 SYBR Green 1 Master Kit 
(Roche, Indianapolis, United States). PCR mix for each sample was prepared 
in triplicates and loaded into Roche Light Cycler 480 (LC480) instrument. 
Light cycler 480 software (version 1.3.0.0705) was used for analysis by 
following manufacturer’s instructions. Primers specific to Sirt1, Sharp-1 and 
GAPDH are shown in Table V. 
2.17  Statistical Analysis 
All graphs in the results section show mean values with error bar indicates 
standard deviation (SD). Statistical significance was determined by two-tailed, 
un-paired Student’s t test and p values of <0.05 were considered to be 
statistically significant. Different statistical significance values were indicated 
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3.  Results 
3.1  Sharp-1 plays a role in cellular senescence 
Studies from our lab have previously demonstrated that overexpression of 
Sharp-1 leads to growth arrest (Liu et al., 2010). To investigate whether 
Sharp-1 has the ability to induce premature senescence, we first examined 
whether Sharp-1 mediated growth arrest leads to cellular senescence. A 
doxycycline inducible Myc-tagged Sharp-1 expressing NIH3T3 cell line was 
used (Liu et al., 2010). To verify the expression of Myc-Sharp-1 upon 
induction, cells were induced with doxycycline (2 µg/ml) for 24 hours prior to 
lysis in RIPA lysis buffer. Cell lysates were analyzed by western blot and 
Myc-Sharp-1 expression was determined using anti-Myc antibody. Compared 
with uninduced cells, western blot analysis clearly showed that Myc-Sharp-1 
was expressed upon doxycycline induction. However, for uninduced cells, the 
basal level of Sharp-1 was not detectable. ß-actin expression was used as 
internal control for equal protein loading (Figure 3.1.1).  
 
Figure 3.1.1 Sharp-1 is expressed upon doxycycline induction. A 
doxycycline inducible Myc-Sharp-1 expressing NIH3T3 cell line was used. 
Expression of Myc-Sharp-1 was determined using western blot analysis for 
cells with or without doxycycline induction by probing with anti-Myc 
antibody. ß-actin was used as internal control for equal protein loading. 
 
 
- 55 - 
 
To demonstrate that Sharp-1 inhibits growth arrest, colony forming assays 
were performed. NIH3T3 cells were plated in triplicates at density of 500 cells 
per plate in 6 cm plate either in the presence or absence of doxycycline. Cells 
were stained with crystal violet after culturing for 14 days. Sharp-1 expressing 
cells showed a clearly reduced colony numbers compared to control (Figure 
3.1.2A). To verify the repression of growth induced by Sharp-1 was 
significant, crystal violet dye was extracted in 1% SDS and absorbance was 
read at 570 nm. Quantification of triplicate assays showed that Sharp-1 
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Figure 3.1.2 Sharp-1 causes growth arrest. Colony forming assays were 
performed with NIH3T3 cells in the presence or absence of doxycycline. (A) 
Colonies were stained with crystal violet at day 14 and data are representative 
of three independent experiments. (B) Crystal violet dye was extracted with 1% 
SDS and the absorbance was measured at wavelength of 570 nm. Bar chart 
was plotted and error bars indicated standard deviations for triplicates for each 
sample. p-value was calculated using two-tailed, un-paired Student’s t test and 
the significance is shown [* p < 0.05; **  p < 0.01; ***  p < 0.001].  
 
 
To study the role of Sharp-1 in cellular senescence, inducible NIH3T3 cells 
were seeded at a density of 5 x 10
3 
cells per well in 6-well plate and cultured 
in the presence or absence of doxycycline for seven days. Expression of Myc-
Sharp-1 upon doxycycline induction was checked by western blot analysis 
(Figure 3.1.3A) Senescence was determined using Senescence Cells 
Histochemical Staining Kit (Sigma Aldrich, USA). The principle of this kit is 
based on the histochemical staining for ß-galactosidase activity at pH6 as this 
activity is easily detected in senescent cells due to expanded lysosomal 
compartment and mass but it is undetectable in either quiescent or tumor cells 
- 57 - 
 
and normal proliferating cells as lysosomal ß-galactosidase activities in these 
cells are usually detected at an acidic pH (pH4) rather than a neutral pH (pH6) 
(Kurz et al., 2000; Yang and Hu, 2005). The SA-ß-gal positive cells generally 
display blue perinuclear staining under bright-field microscopy with profound 
changes of their morphologies. Myc-Sharp-1 expressing cells displayed a 
much higher number of blue cells compared with uninduced cells. In addition, 
Myc-Sharp-1 expressing cells also showed morphological changes as they 
looked more flattened, enlarged with irregular shapes together with increased 
nucleus and nucleoli sizes (Figure 3.1.3B) which are the typical characteristics 
of senescent cells (Chen et al., 2000).  
To determine whether the cellular senescence induced by Sharp-1 expression 
is significant, at least 300 cells from 5 fields were counted for both control and 
Myc-Sharp-1 expressing cells.  The percentage of senescent cells was 
calculated by using number of blue stained cells/the total number of cells X 
100% and the significance was determined by p-value using two-tailed, un-
paired Student’s t test. Quantification of the results showed that 23.74% of the 
cells underwent senescence in Sharp-1 expressing cells whereby only 4.63% 
of senescence was observed in uninduced cells (Figure 3.1.3C), indicating that 












Figure 3.1.3 Sharp-1 induces cellular senescence. (A) Expression of Myc-
Sharp-1 was determined using western blot analysis for cells with or without 
doxycycline induction by probing with anti-Myc antibody. ß-actin was used as 
internal control for equal protein loading. (B) Sharp-1 expressing inducible 
cells were induced with or without doxycycline and seeded for senescence 
assay. Senescence was determined for both uninduced and induced cells after 
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seven days culturing under normal conditions using histochemical staining kit. 
Cells were examined using bright-field microscope and positive SA-ß-gal 
senescent cells showed blue staining with morphological changes under 20X 
magnification.  (C) Percentages of positive SA-ß-gal senescent cells were 
calculated and presented in bar chart as means with standard deviation (error 
bar). p-values were calculated using two-tailed, un-paired Student’s t test and 
the significance is shown [* p < 0.05; **  p < 0.01; ***  p < 0.001].  
 
 
3.2  Effect of Sharp-1 on intracellular ROS production 
Growing evidence suggests that cellular senescence can be triggered by either 
exogenous introduction of ROS or intracellular ROS generation. We therefore 
tested whether overexpression of Sharp-1 in cells increases intracellular ROS 
level that is correlated to the premature senescence we observed. 
3.2.1 Sharp-1 produces intracellular ROS 
To detect for Sharp-1 induced intracellular ROS production, cells were 
cultured in the presence or absence of doxycycline for 24 hours. The levels of 
ROS were assessed using fluorescent probe CM-H2DCFDA which was then 
analyzed with flow cytometry. Uninduced NIH3T3 cells which treated with 
150 µM H2O2 for 30 minutes were used as positive control of ROS production. 
Our data clearly revealed that Sharp-1 expressing cells had an increased level 
of intracellular ROS compared with uninduced cells (Figure 3.2.1), supporting 
the idea that Sharp-1 enhances intracellular ROS production.  
A. 
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Figure 3.2.1 Sharp-1 induces intracellular ROS production. Intracellular 
ROS levels in both uninduced and induced cells were measured by staining 
with CM-H2DCFDA fluorescent probe and analyzed by FACS. Uninduced 
cells that exposed to 150µM of H2O2 for half an hour was used as positive 
control as H2O2 treatment is known to increase intracellular ROS level.  
 
3.2.2  Sharp-1 Produced ROS can be Scavenged by NAC 
Next, we examined whether N-acetylcysteine (NAC), a potent antioxidant 
which interacts directly with hydroxyl radicals (Cuzzocrea et al., 2001) and 
nitrogen species (Zhang et al., 2011), could inhibit the accumulation of ROS 
produced by Sharp-1. Cells were incubated with or without 2 mM NAC for 16 
hours in the presence or absence of doxycycline induction. Intracellular ROS 
levels were measured by incubating cells with CM-H2DCFDA fluorescent 
probe and analyzed by FACS. As shown in Figure 3.2.2, the enhanced ROS 
level from doxycycline induced Sharp-1 expressing cells was almost 
completely blocked by incubation with NAC.  
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Figure 3.2.2 NAC rescues Sharp-1 enhanced ROS level. Control and Myc-
Sharp-1 expressing cells were treated with or without 2mM of NAC for 2 
hours prior to staining with 5µM CM-H2DCFDA and subjected to flow 
cytometry. Cells treated with 150 µM of H2O2 for half an hour was used as 
positive control.  
 
3.2.3 Sharp-1 mediated ROS production correlates with its ability to 
cause cellular senescence 
Senescence is known to be associated with enhanced intracellular ROS (Lee et 
al., 1999; Macip et al., 2003), since we have demonstrated that Sharp-1 is able 
to increase ROS level and also to induce cellular senescence, we investigated 
the correlation between Sharp-1 enhanced intracellular ROS levels and Sharp-
1 mediated cellular senescence. To determine this, cells with or without 
doxycycline induction and in the presence or absence of 2 µM NAC were 
cultured in 6-well plate under normal conditions for seven days. If Sharp-1 
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generated ROS is involved in its mediated cellular senescence, treatment with 
NAC would be expected to lower the percentage of senescent cells compared 
with cells without NAC treatment. Expression of Myc-Sharp-1 was checked 
by western blot analysis using anti-Myc antibody which showed Myc-Sharp-1 
level was not affected by NAC treatment (Figure 3.2.3A). Consistent with our 
previous results, senescent cells were observed in Sharp-1 expressing cells 
compared with uninduced cells. Interestingly, less senescent cells were 
observed in NAC treated Sharp-1 expressing cells compared with untreated 
cells (Figure 3.2.3B). Quantification of the data showed that NAC treatment 
was able to significantly decrease the percentage of senescent cells from 22.6% 
to 12.87% in Sharp-1 expressing cells (Figure 3.2.3C), supporting the idea that 
the enhanced intracellular ROS level by Sharp-1 is involved in Sharp-1-
mediated cellular senescence as lowering ROS level by NAC leads to reduced 









Figure 3.2.3 NAC blocks Sharp-1 generated intracellular ROS and 
partially rescues Sharp-1 mediated cellular senescence. Myc-Sharp-1 
inducible cells were treated in the presence or absence of doxycycline and 
incubated with or without 2µM of NAC for senescence assays. (A) Expression 
of Myc-Sharp-1 was checked by western blot analysis using anti-Myc 
antibody. ß-actin was used as internal control for equal loading. (B) SA-ß-gal 
senescence assays were performed on cells after seven days of culturing and 
examined under light microscope with 10X magnification. (C) Percentages of 
positive SA-ß-gal senescent cells were calculated and presented in bar chart as 
means with standard deviation (error bar). p-value was calculated using two-
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tailed, un-paired Student’s t test and the significance is shown as [* p < 0.05; 
** p < 0.01; *** p < 0.001].  
 
 
3.3  Sharp-1-mediated cellular senescence is p53 dependent 
Our group has previously showed Sharp-1 mRNA was up-regulated by 
genotoxic stress and overexpression of Sharp-1 induced S and G2/M cell cycle 
arrest. In addition, Sharp-1 overexpressed cells showed a reduced apoptotic 
response when exposed to DNA damaging drugs (Liu et al., 2010). Similar to 
what our group has found, few other groups have also demonstrated that Dec2, 
a human homologue of Sharp-1, displayed an anti-apoptotic effect in breast 
cancer cell lines as knockdown of Dec2 by siRNA led to increased apoptosis 
due to altered expression levels of pro-apoptotic factors (Sato et al., 2008; Liu 
et al., 2010). Moreover, Sharp-1 expression levels decline in lung cancer. All 
of these observations suggest Sharp-1 might function as a potential tumor 
suppressor. Since cellular senescence is an important mechanism to suppress 
tumorigenesis and p53 is the major regulator in senescence pathway, we 
explored whether Sharp-1 induced cellular senescence is p53 dependent.  
To ascertain this, senescence assays were performed with siRNA knockdown 
of p53 (sip53) in Myc-Sharp-1 expressing NIH3T3 cells. Cells were 
transfected with either scramble siRNA control or sip53. 48 hours after 
transfection, cells were collected and lysates were checked by western blot for 
Myc-Sharp-1 and p53 expression before seeding for senescence assays. Cells 
were cultured under normal conditions for seven days and stained with 
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Senescence Cells Histochemical Staining kit. Expression of Myc-Sharp-1 and 
endogenous p53 were detected by western blot analysis using anti-Myc and 
anti-p53 antibodies, respectively. Senescent cells were examined using light 
microscope and the results supported that Sharp-1 has the ability to cause 
senescence. Western blot results demonstrated that endogenous p53 level was 
enhanced in Myc-Sharp-1 overexpressed cells (Figure 3.3A). Knockdown of 
p53 in Myc-Sharp-1 expressing cells almost completely blocked cellular 
senescence that was induced in Sharp-1 cells transfected with scramble siRNA 
control  (Figure 3.3B and C), suggesting that Sharp-1 indeed functions as an 
upstream regulator of p53. In addition, Sharp-1 requires p53 to induce 
senescence as Sharp-1 expressing cells fail to undergo cellular senescence 









Figure 3.3 Sharp-1 induced cellular senescence is p53 dependent. (A) 
NIH3T3 cells in the presence or absence of doxycycline was transfected with 
either scramble siRNA control or sip53. Cells were lysed and lysates were 
analyzed by western blot to check for the expressions of Myc-Sharp-1 and p53. 
(B) Cells were seeded for senescence assays and cultured for 7 days followed 
by SA-ß-gal staining. (C) Quantification of percentage of SA-ß-gal positive 
cells was plotted in bar chart and asterisk indicates significance of the 
difference (p < 0.05). 
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3.4 Sharp-1 associates with p53 and positively regulates it 
3.4.1  Sharp-1 interacts with p53 
We have shown that Sharp-1 requires p53 to induce cellular senescence. We 
next wanted to investigate the possible relationship between Sharp-1 and p53. 
Despite the lack of reports of the relationship between Sharp-1 and p53, clues 
of a possible relation between these two proteins can be inferred from Stra13, 
a member of the same subfamily as Sharp-1. Stra13 associates with p53 
through its bHLH domain, and increases p53 levels in a mouse double 
mutant2 (Mdm2)-dependent manner by preventing Mdm2-mediated 
ubiquitination and nuclear export of p53 (Thin et al., 2007). Since Sharp-1 and 
Stra13 share 95% homology within the bHLH domain, a similar interaction 
and regulation between Sharp-1 and p53 is plausible. 
NIH3T3 cells were co-transfected with p53 and Myc-Sharp-1 expression 
vectors either individually or together. Expressions of p53 and Sharp-1 were 
determined by western blot analysis. Cell lysates were incubated and 
immunoprecipitated with anti-Myc agarose beads and immunoblotted with 
anti-p53 antibody. Co-immunoprecipitation result showed that Sharp-1 
associated with p53 (Figure 3.4.1). This finding prompted us to study if Sharp-
1, like Stra13, has the ability to regulate p53.  
- 68 - 
 
 
Figure 3.4.1 Interaction between Sharp-1 and p53. Sharp-1 and p53 were 
co-transfected in NIH3T3 cells. Cells were lysed and expressions of the 
desired proteins were analyzed by western blotting with anti-Myc and anti-p53 
antibodies. β-actin was used as an internal loading control. Co-
immunoprecipitation was carried out in which Myc-Sharp-1 was 
immunoprecipitated with anti-Myc-agarose beads and the interaction with p53 
was detected with anti-p53 antibody. 
 
 
3.4.2  Sharp-1 positively regulates p53 by increasing its total and 
acetylated levels 
In order to study the possible regulation between Sharp-1 and p53, NIH3T3 
cells were co-transfected with p53 and Myc-Sharp-1 either individually or at 
ratios 1:1, 1:3 and 1:6. Cell lysates were collected and immunoblotted with 
anti-p53 antibody. As shown in Figure 3.4.2, Sharp-1 expression enhanced the 
amount of total p53 in a dose dependent manner.  
Increased p53 protein levels could due to either decreased Mdm2-mediated 
proteasomal degradation or increased p53 stability by post-translational 
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modifications. Our lab has previously reported that Stra13 positively regulates 
p53 by preventing Mdm2-mediated ubiquitination and nuclear export (Thin et 
al., 2007). In addition, acetylation of p53 increases its stability (Ito et al., 
2001). Since both ubiquitination and acetylation occur on the same lysine sites 
at C-terminal of p53, it is possible that elevated p53 levels induced by Sharp-1 
are due to the competition between ubiquitination and acetylation, i.e. Sharp-1 
might increase p53 acetyl and total levels thereby preventing Mdm2 mediated 
p53 ubiquitination and degradation.  
To address this, cell lysates were analyzed by immunoblotting using anti-
acetyl p53 at Lys 379.  Western blot result showed that acetyl p53 level was 
also increased in a dose dependent manner (Figure 3.4.2). This in vitro data 
suggest that Sharp-1 might not only positively regulate total p53 levels but 
also its acetylation status.  
 
Figure 3.4.2 Sharp-1 positively regulates p53 acetyl and total levels. 
NIH3T3 cells were co-transfected with expression vectors for p53 and Myc-
Sharp-1 at the indicated ratios. Cell lysates were analyzed by western blot and 
acetyl-p53, p53 and Myc-Sharp-1 expressions were determined by anti-acetyl-
p53, anti-p53 and anti-Myc antibodies, respectively. ß-actin was used as 
internal control for equal loading.  
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3.4.3 Sharp-1 positively regulates p53 ex vivo  
To validate the findings that Sharp-1 regulates p53 levels, we examined the 
p53 levels using mouse embryonic fibroblasts (MEFs) derived from Sharp-1 





were seeded in 6cm plates which were then treated with or without DNA 
damaging drug-cisplatin (20 µM) for 24 hours. Cells were harvested and 
acetyl p53 level and total p53 level were detected by western blot analysis. As 
predicted, p53 levels increased when cells were exposed to cisplatin compared 
to untreated cells (Figure 3.4.3). In addition, in agreement with previous data 
(Figure 3.4.2), Sharp-1 knockout MEFs showed a reduced level of total p53 
compared to wild type MEFs. Moreover, acetyl level of p53 at K379 in Sharp-
1 knockout MEFs was also reduced compared to the wild type MEFs (Figure 
3.4.3). These data support our hypothesis that endogenous Sharp-1 indeed 
could affect p53 regulation where Sharp-1 possibly acts upstream of p53 
which modulates p53 stability and may thus promote its activation. 
 
Figure 3.4.3 Regulation of p53 levels by Sharp-1 in MEFs. Primary mouse 





) were treated with or without cisplatin (20 µM) for 24 hours. Cell 
lysates were collected and analyzed for acetylated p53 and total p53 level. ß-
actin was used as loading control.    
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3.5  Sharp-1 associates with Sirt1  
It has been reported that Sharp-1 recruits co-repressors such as HDAC1, Sirt1 
or G9a (Fujimoto et al., 2007; Ling et al., 2013) to mediate transcriptional 
repression. However, the functional significance of these interactions remains 
unknown. Earlier on we have demonstrated that Sharp-1 mediated cellular 
senescence is p53 dependent, and that it positively regulates p53 activation at 
K379. Moreover, Sharp-1 induced senescence involves enhanced intracellular 
ROS levels. Sirt1, a class III HDAC deacetylase, directly interacts with p53 
and deacetylates it at K379 (Luo et al., 2001; Varizi et al., 2001). Upon 
deacetylation, Sirt1 inhibits p53-mediated biological functions by reversing 
the acetylation modification on p53 which is carried out by acetyltransferase 
(Langley et al., 2002). In addition, Sirt1 is also known to inhibit ROS 
production by increasing catalase levels. Therefore, we were interested to 
investigate whether the association between Sharp-1 and Sirt1 is important for 
regulation of p53 and its functions.  
3.5.1  Sharp-1 binds to Sirt1 
We first examined whether Sharp-1 interacts with Sirt1 by co-
immunoprecipitation assays. NIH3T3 cells were co-transfected with full 
length FLAG-Sirt1 and Myc-Sharp-1 either individually or together. FLAG-
Sirt1 and Myc-Sharp-1 expression was checked by western blot analysis. 
FLAG-Sirt1 was immunoprecipitated with anti-FLAG agarose beads and 
Myc-Sharp-1 was detected by immunoblotting with anti-Myc antibody. A 
clear association between Sharp-1 and Sirt1 was evident (Figure 3.5.1).  
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Figure 3.5.1 Interaction between Sharp-1 and Sirt1. Myc-Sharp-1 and 
FLAG-Sirt1 were co-transfected in NIH3T3 cells. Cells were lysed and 
expressions of the desired proteins were analyzed by western blot with anti-
Myc and anti-FLAG antibodies. β-actin was used as an internal loading 
control. Co-immunoprecipitation was carried out in which FLAG-Sirt1 was 
immunoprecipitated with anti-FLAG agarose beads and the presence of Myc-
Sharp-1 was detected with anti-Myc antibody. 
 
 
3.5.2  Sharp-1 and Sirt1 co-localize in the nucleus 
We examined the sub-cellular localization of Sharp-1 and Sirt1 by 
immunofluorescence staining. NIH3T3 cells were transfected with either 
FLAG-Sirt1 or Myc-Sharp-1 alone or together. 24 hours after transfection, 
cells were fixed and stained with fluorescence conjugated secondary 
antibodies. Nuclei were stained with DAPI (blue). Fluorescence microscopy 
indicated that both Sharp-1 (red) and Sirt1 (green) are nuclear proteins and co-
localize in the nucleus (Figure 3.5.2).  
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Figure 3.5.2 Sharp-1 and Sirt1 co-localized in the nucleus. NIH3T3 cells 
were co-transfected with Myc-Sharp-1 and FLAG-Sirt1. Co-localization of 
Sharp-1 and Sirt1 was analyzed by immunofluorescence staining using anti- 
Myc antibody (red) and anti-FLAG antibody (green). Nuclei were stained with 
DAPI (blue). The images were merged and co-localization of these proteins 
was visualized by yellow fluorescence. Images were captured under a 
microscope with 20x magnification. 
 
 
3.5.3  Sharp-1 directly binds to Sirt1 
To examine if the interaction between Sharp-1 and Sirt1 is direct, glutathione 
S-transferase (GST) pull down assays was performed. GST and GST-Sharp-1 
were induced with isopropyl-beta-D-thiogalactopyranoside (IPTG) in E.coli 
BL21 (DE3) cultures. Both GST and GST-Sharp-1 proteins were purified 
using Glutathione Sepharose 4B beads and detected by coomassie blue 
staining on SDS-PAGE gels. The amount of GST protein and GST-Sharp-1 
protein were quantified. FLAG-Sirt1 was transcribed and translated in vitro 
using TNT coupled reticulocyte lysate system. The same amount (15 μg) of 
GST and GST-Sharp-1 proteins were incubated with FLAG-Sirt1, followed by 
glutathione-sepharose beads. Proteins immobilized on glutathione-sepharose 
beads were subjected to western blot analysis with anti-FLAG antibody. 10% 
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of in vitro translated Sirt1 protein was loaded as a control. GST-Sharp-1, but 
not GST, interacted with FLAG-Sirt1, demonstrating that Sirt1 interacts 
directly with Sharp-1 (Figure 3.5.3). 
 
Figure 3.5.3 Sharp-1 directly interacts with Sirt1. In vitro translated FLAG-
Sirt1 was incubated with GST or GST-Sharp-1 fusion proteins to determine its 
direct protein interaction. 10% of FLAG-Sirt1 used in pull-down assay was 
used as input and detected by western blot with anti-Flag antibody. 
 
 
3.5.4  Sharp-1 interacts with Sirt1 through its bHLH domain 
3.5.4.1 Sharp-1 interacts with Sirt1 via its bHLH domain 
To further define the region in Sharp-1 that associates with Sirt1, NIH3T3 
cells were co-transfected with FLAG-Sirt1 and Myc-Sharp-1 full length or 
various deletion mutants (Figure 3.5.4A) generated by our lab (Gulbagci et al., 
2009; Ling et al., 2012). Cells were harvested and lysates were analyzed by 
western blot to check the expression of FLAG-Sirt1 and Myc-Sharp-1 mutant 
constructs. Cell lysates were immunoprecipitated with anti-Myc agarose beads 
and the presence of FLAG-Sirt1 was detected by immunoblotting with anti-
FLAG antibody. Like full length Sharp-1, Sirt1 was able to bind to all Sharp-1 
deletion mutants. This observation suggests that the C-terminus of Sharp-1 is 
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not required for Sirt1-Sharp-1 interaction. In addition, the association between 
Sirt1 and Sharp-1 occurs at the N-terminus within a region encompassing the 
bHLH domain (Figure 3.5.4B). 
A  
 






Figure 3.5.4 Mapping of the functional domain of Sharp-1 required for 
Sirt1 binding.  (A) Schematic representation of full-length Sharp-1 (1-410) 
and its deletion mutants. b, basic region; HLH, helix-loop-helix domain; O, 
orange domain. (B) NIH3T3 cells were transfected with all the Myc-Sharp-1 
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constructs (showed in A) and Flag-Sirt1. Cell lysates were analyzed for 
expressions of various Myc-Sharp-1 constructs and Sirt1 using western blot. 
ß-actin was used as internal control for equal loading. Lysates were then 
immunoprecipitated with anti-Myc agarose beads and immunoblotted with 




3.6. Sirt1 modulates Sharp-1-mediated p53 regulation 
Acetylation is important for p53 stability and transcriptional activity as 
unstable p53 is subjected to Mdm2-mediated proteasomal degradation. Since 
Sharp-1 positively regulates p53 acetylation at K379 whereas Sirt1 
deacetylates p53 at the same lysine site and inhibits p53 mediated biological 
functions, we tested whether Sharp-1 and Sirt1 function in an antagonistic 
manner to regulate p53. To determine the role of Sirt1 in Sharp-1 mediated 
increase of p53 acetylation, NIH3T3 cells were co-transfected with p53 and 
Myc-Sharp-1 at the indicated ratios (1:3 or 1:6). 24 hours after transfection, 
cells were treated with either a Sirt1 activator (resveratrol, 2.5 µM) or an 
inhibitor (sirtinol, 25 µM) for 24 hours to alter endogenous Sirt1 activity. 
Cells were then lysed and lysates were analyzed by western blot using both 
anti-acetyl p53 and anti-p53 antibodies. Sharp-1 expression was checked with 
anti-Myc antibody and ß-actin was used as internal control.  Sirt1 activity was 
enhanced by resveratrol and reduced by sirtinol which in turn altered 
acetylated p53 levels. As demonstrated earlier, increasing amounts of Sharp-1 
resulted in increased acetylated and total p53 levels (Figure 3.6.1. lanes 1 and 
3). When treated with resveratrol, Sirt1 activity is enhanced which caused 
acetylated p53 levels to drop significantly (Figure 3.6.1. lane 2 and 4 from top 
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panel) compared with untreated cells (Figure 3.6.1. lane 1 and 3 from top 
panel). In cells treated with sirtinol, which inhibits Sirt1 activity, acetyl p53 
levels were enhanced and higher than untreated cells (Figure 3.6.1. lane 5 and 
6). These data support the idea that Sirt1 and Sharp-1 work as antagonists to 
regulate p53 acetylation. 
 
Figure 3.6 Regulation of p53 is affected by Sharp-1 and Sirt1. NIH3T3 
cells were co-transfected with expression vector for p53 and Myc-Sharp-1 at 
the indicated ratios. Cells were treated with DMSO, resveratrol (Sirt1 activator) 
or sirtinol (Sirt1 inhibitor) for 24 hour prior to lysis. Cell lysates were 
analyzed for acetylated p53 and total p53 levels by western blot. Expression 
level of Myc-Sharp-1 was detected and ß-actin was used for loading control. 
 
3.7   Sirt1 reverts Sharp-1 mediated growth arrest  
It is reported that deacetylation of p53 by Sirt1 blocks its biological function 
(Yi and Luo, 2010). In addition, we also demonstrated that increasing Sirt1 
activity using resveratrol counteracted Sharp-1 mediated enhancement of p53 
acetylation (Figure 3.6). Hence, it is possible that Sirt1 blocks Sharp-1 
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mediated functions. To test our hypothesis, colony forming assays were 
carried out with NIH3T3 cells that transfected with either empty vector, Myc-
Sharp-1, FLAG-Sirt1 individually or together. Cells were then seeded in 
triplicates at a density of 500 cells per 6 cm plate and cultured for 14 days. 
Expression of FLAG-Sirt1 and Myc-Sharp-1 were checked by western blot 
analysis using anti-FLAG and anti-Myc antibodies. ß-actin was used as 
loading control (Figure 3.7A). Colonies were stained with crystal violet dye. 
The results were consistent with our previous data in which the number of 
colonies was significantly decreased in Sharp-1 expressing cells compared 
with control cells. In addition, number of colonies in Sharp-1 expressing cells 
was clearly increased in the presence of Sirt1 (Figure 3.7B). To determine the 
significance levels, the data were quantified based on relative absorbance 
which demonstrated that overexpression of Sirt1 significantly rescued Sharp-1 










Figure 3.7 Sirt1 rescues Sharp-1 mediated growth arrest. Colony forming 
assays were performed with NIH3T3 cells which were co-transfected with 
FLAG-Sirt1 and Myc-Sharp-1 either individually or together in triplicates in 
6-cm plates. (A) Expression of FLAG-Sirt1 and Myc-Sharp-1 were detected 
using western blot analysis with anti-FLAG and anti-Myc antibodies. ß-actin 
was used as loading control. (B) Colonies were visualized by staining with 
crystal violet dye at day 14 and data are representative of three independent 
experiments. (C) Crystal violet dye was extracted with 1% SDS and the 
absorbance was measured at wavelength of 570nm. Bar chart was plotted and 
error bars indicated standard deviations for triplicates for each sample. p-value 
was calculated using two-tailed, un-paired Student’s t test and the significance 
is shown as * p < 0.05; **  p < 0.01; *** p < 0.001. 
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3.8  Sirt1 rescues Sharp-1 mediated cellular senescence 
3.8.1 Alteration of Sirt1 activity modulates Sharp-1 mediated senescence 
We have demonstrated that Sirt1 could rescue Sharp-1 mediated growth arrest. 
Since growth arrest is one of the characteristics of cellular senescence, we 
hypothesized that Sirt1 would also be able to rescue Sharp-1 induced 
senescence. To address this, Sharp-1 overexpressing NIH3T3 cells were 
treated with resveratrol to increase endogenous Sirt1 activity. Upon treatment, 
cells were lysed and checked for Sharp-1 expression before seeding for 
senescence assay. Western blot data indicated that expression level of Myc-
Sharp-1 was not affected by treatment with resveratrol (Figure 3.8.1A).  
Cells with or without Myc-Sharp-1 overexpression and in the presence or 
absence of resveratrol were seeded in 6-well plate with cell density at 5 x 10
3
/ 
well. Cells were cultured for seven days and analyzed for senescence. 
Consistent with our previous results, Sharp-1 expressing cells had higher 
senescent cell numbers compared with cells transfected with empty vector. In 
addition, number of senescent cells decreased when cells were treated with 
resveratrol compared with untreated cells (Figure 3.8.1B).  
At least 300 cells from 5 different fields were counted and percentage of 
senescence was calculated. Increase in Sirt1 activity significantly reduced the 
percentage of senescent cells from 23.2% to 13.67% in Sharp-1 expressing 
cells (Figure 3.8.1C) 
A.  
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Figure 3.8.1 Treatment with resveratrol reverts Sharp-1 mediated cellular 
senescence in NIH3T3 cells. NIH3T3 cells were transfected with Myc-Sharp-
1 or empty vector in the presence or absence of resveratrol (25 µM) for 24 
hours prior to lysis. (A) Expression of Myc-Sharp-1 was checked by 
immunoblotting with anti-Myc antibody. ß-actin was used for loading control. 
(B) Senescence assays were carried out with Sharp-1 overexpressed cells 
treated with or without resveratrol. SA-ß-gal staining was used to identify 
senescent cells. (C) The percentage of SA-ß-gal positive cells was quantified. 
Asterisk indicates significance values (p < 0.05). 
 
 
3.8.2  Sirt1 expression inhibits Sharp-1 mediated senescence  
To further validate these results, Sirt1 expression was increased by transient 
transfection. FLAG-Sirt1 and Myc-Sharp-1 were co-transfected in NIH3T3 
cells either individually or together and seeded for senescence assays. Indeed, 
senescence assays results confirmed that Sharp-1 overexpression resulted in 
showed higher senescent cell numbers compared with control cells. Moreover, 
increased expression of FLAG-Sirt1 significantly reduced the number of 
senescent cells in Myc-Sharp-1 expressing cells (Figure 3.8.2A) from 23.7% 
to 8.97% (Figure 3.8.2B). Cells seeded for senescence assays were harvested 
and lysed for western blot analysis. Western blot results reasserted the staining 
data in which Sharp-1 overexpression alone was able to increase both acetyl 
and total p53 levels, whereas overexpression of Sirt1 in Sharp-1 expressing 
cells caused a reduction of both acetyl p53 and total p53 levels (Figure 3.8.2C).  
So far, we have demonstrated that Sirt1 is able to inhibit Sharp-1 mediated 
cellular senescence either by increasing its activity or its expression and these 
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data support our hypothesis that Sirt1 functions as an antagonist of Sharp-1 
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Figure 3.8.2 Sirt1 blocks Sharp-1 mediated cellular senescence. (A)  
Senescence assays were performed on Sharp-1 overexpressing cells with and 
without ectopic expression of FLAG-Sirt1. SA-ß-gal staining was used to 
identify senescent cells. (B) Quantification of SA-ß-gal positive cells was 
plotted and significance was calculated and is indicated with an asterisk. (C) 
Cells seeded for senescence assay were harvested and lysates were analyzed 
using western blot with anti-acetyl p53 and anti-p53 antibodies. FLAG-Sirt1 
and Myc-Sharp-1 expressions were detected by anti-FLAG and anti-Myc 
antibodies, respectively. ß-actin was used for loading control. 
 
 
3.9  Regulation between Sirt1 and Sharp-1 
We then investigated possible underlying mechanisms by which Sharp-1 and 
Sirt1 antagonize each other to regulate p53. Since Sharp-1 and Sirt1 directly 
interact with each other, and both of them affect p53 acetylation, it is possible 
they regulate each other via three ways. (a) Sharp-1 might act upstream of 
Sirt1 and inhibit Sirt1 function, rendering it unable to deacetylate p53, 
resulting an increased acetylation of p53. (b) Sirt1 could act upstream of 
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Sharp-1 and blocks Sharp-1 function, leaving it unable to positively regulate 
p53 acetylation. As a result, both acetyl p53 and total p53 levels decrease and 
p53 mediated biological functions are also inhibited. (c) Sharp-1 and Sirt1 
could function in parallel pathways to affect p53 mediated cellular functions. 
In other words, Sirt1 mediated deacetylation of p53 is independent of Sharp-1 
mediated acetylation of p53.  
3.9.1  Effect of Sharp-1 on Sirt1 expression 
To narrow down the possible regulation between Sharp-1 and Sirt1, we first 
tested whether Sharp-1 could regulate Sirt1 by inhibiting its expression. 
NIH3T3 cells were transfected with either Myc-Sharp-1 or empty vector. 
Upon harvesting, cells were lysed and lysates were analyzed by western blot 
to detect for endogenous Sirt1. Sirt1 expression was not affected by ectopic 
expression of Sharp-1 suggesting that Sharp-1 does not act upstream to 
regulate Sirt1 expression (Figure 3.9.1).  
 
Figure 3.9.1 Overexpression of Sharp-1 does not alter Sirt1 expression 
level. NIH3T3 cells were transfected with either empty vector or Myc-Sharp-1. 
Cells were lysed and analyzed by western blot to detect for the endogenous 
Sirt1 levels using anti-Sirt1 antibody. Expression of Myc-Sharp-1 was 
detected by anti-Myc antibody and ß-actin was used as loading control.  
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3.9.2 Effect of Sirt1 on Sharp-1 transcription 
Since overexpression of Sharp-1 does not alter Sirt1 expression, we then tested 
whether Sirt1 acts upstream of Sharp-1 and affects Sharp-1 expression.  To 
address this, NIH3T3 cells were transfected with FLAG-Sirt1 or empty vector. 
Total mRNA from the transfected cells was extracted and analyzed by 
quantitative real-time PCR (Q-PCR) to check for Sharp-1 expression. 
Overexpression of Sirt1 was confirmed by Q-PCR in cells transfected with 
FLAG-Sirt1 (Figure 3.9.2A). Sharp-1 mRNA levels were similar in both 
control and Sirt1 overexpressed cells (Figure 3.9.2 B) indicating that Sirt1 
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Figure 3.9.2 Overexpression of Sirt1 does not affect Sharp-1 transcription. 
NIH3T3 cells were transfected with either empty vector or FLAG-Sirt1. 
Relative expression of (A) FLAG-Sirt1 and (B) Sharp-1 mRNA were 
quantified by normalizing to house-keeping gene GAPDH and were plotted in 
bar chart as mean with standard deviation. The data was provided by Shilpa 
Rani Shankar.  
 
 
3.9.3 Effect of Sirt1 on Sharp-1 deacetylation  
Being a deacetylase, Sirt1 deacetylates both histone and non-histone targets. 
Though Sirt1 does not alter Sharp-1 mRNA levels, we investigated whether 
Sirt1 has the ability to deacetylate Sharp-1. To verify this, NIH3T3 cells were 
co-transfected with FLAG-Sirt1 and Myc-Sharp-1 either individually or 
together. Cells were collected and lysates were analyzed by western blot to 
check for expression of Sirt1 and Sharp-1. Lysates were incubated and 
immunoprecipitated with anti-acetyl lysine (AcK) agarose beads and the 
presence of Myc-Sharp-1 was detected by immunoblotting with anti-Myc 
antibody. Co-immunoprecipitation results showed that Sirt1 indeed 
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deacetylates Sharp-1 (Figure 3.9.3). These results suggest that one mechanism 
by which Sirt1 may block Sharp-1 function is via deacetylation.  
 
Figure 3.9.3 Sirt1 is able to deacetylate Sharp-1. NIH3T3 cells were co-
transfected with FLAG-Sirt1 and Myc-Sharp-1. Upon harvesting the cells, 
lysates were checked for the expressions of FLAG-Sirt1 and Myc-Sharp-1 by 
western blot analysis; ß-actin was used as internal control. Co-
immunoprecipitation assays were performed in which lysates were 
immunoprecipitated with acetyl lysine agarose beads and the presence of Myc-
Sharp-1 was detected with anti-Myc antibody.  
 
 
3.10  Knockdown of Sirt1 does not affect Sharp-1 mediated cellular 
senescence 
Sirt1 inhibits Sharp-1 induced cellular senescence likely by functioning as an 
antagonist for Sharp-1. In addition, neither Sharp-1 nor Sirt1 repressed each 
other’s expression. We investigated whether Sharp-1 is upstream of Sirt1 and 
thereby affects Sirt1 activity. To test whether Sirt1 is downstream of Sharp-1, 
siRNA knockdown approach was used. Sharp-1 expressing NIH3T3 cells were 
transfected with either scrambled siRNA as a control, or siRNA targeted to 
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Sirt1 (siSirt1). 48 hours after transfection, part of the cells was seeded for 
senescence assays, and the rest of the cells was lysed and analyzed by western 
blot to check for the expression of Sirt1, as well as both acetyl p53 and total 
p53 levels. If Sharp-1 is upstream of Sirt1, and inhibits Sirt1 activity, 
knockdown of Sirt1 should impact Sharp-1 dependent senescence. Western 
blot showed that Sirt1 expression was reduced in cells transfected with siSirt1 
compared with siRNA control (Figure 3.10A). Senescence assays were 
performed and results demonstrated that knockdown Sirt1 in Sharp-1 
expressing cells did not affect senescence compared with Sharp-1 
overexpressing cells transfected with scramble siRNA (Figure 3.10B). The 
percentage of senescent cells between Sharp-1 overexpressing cells and siSirt1 
knockdown cells was not significant (Figure 3.10C). Therefore, Sirt1 most 
likely does not function downstream of Sharp-1 as knockdown of Sirt1 does 
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Figure 3.10 Sirt1 does not act downstream of Sharp-1 to regulate cellular 
senescence.  (A) NIH3T3 cells were transfected with either siRNA scramble 
or siRNA targeted to Sirt1 in the presence or absence of Sharp-1. Cells were 
lysed and lysates were analyzed by western blot to check for the expressions 
of Myc-Sharp-1, Sirt1, acetyl p53 and p53 levels. (B) Senescence assays were 
performed and were stained using SA-ß-gal method and visualized under a 
light microscope with 10X magnification. (C) Quantification of SA-ß-gal 
positive cells was plotted as mean with standard deviation (SD) and asterisk 
indicates significance values (p < 0.05). 
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3.11 Sirt1 antagonizes Sharp-1 mediated cellular senescence under 
genotoxic stress 
To confirm that Sharp-1 and Sirt1 antagonize each other to regulate p53 and 
cellular senescence, a double knockdown approach was used.  
NIH3T3 cells were transiently transfected with siRNAs targeted to both Sirt1 
and Sharp-1 for 48 hours. Since p53 levels are up-regulated upon DNA 
damaging stimuli, we also treated cells with etoposide to monitor the impact 
of both Sirt1 and Sharp-1 on endogenous p53 levels. Cells were then treated 
with or without etoposide at 20 µM for 2 hours. Part of the cells was seeded at 
a very low density in 6 well plates for senescence assays, and the rest were 
lysed and used for western blot analysis with anti-Sirt1, anti-Myc, anti-p53 
AcK379 and p53 antibodies to check for protein expression.  
Endogenous Sirt1 levels remained unchanged in the presence of etoposide, 
and were reduced drastically upon transfecting with siRNA for Sirt1. Our lab 
has previously reported that Sharp-1 was up-regulated upon genotoxic stress 
(Liu et al., 2010). Therefore, an increase in Sharp-1 expression should be 
observed when cells are exposed to etoposide. Indeed, Sharp-1 levels were 
increased with etoposide and these levels became undetectable after 
knockdown using siSharp-1. In normal unstressed cells, p53 is inactive and is 
kept at low levels due to degradation by its negative modulator, Mdm2. 
However, under either genotoxic or non genotoxic stress conditions, p53 is 
activated and becomes more stable (Bai and Zhu, 2006; Gambino et al., 2013).  
This is also reflected in our western blot results as both acetyl and total p53 
levels were increased upon etoposide treatment compared with untreated cells. 
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It is known Sirt1 reduces acetyl and total p53 levels by deacetylating it. In 
addition, we have demonstrated that Sharp-1 positively regulates both acetyl 
and total p53 levels (Figure 3.6). Hence, knockdown of Sirt1 by siSirt1 
enhanced both acetyl and total p53 levels, whereas knockdown of Sharp-1 by 
siSharp-1 decreased both acetyl and total p53 levels. Cells which were 
deficient of both Sirt1 and Sharp-1 showed increased p53 levels compared 
with controls as well as cells with single knockdown of Sharp-1 alone, but the 
levels were lower than cells with single knockdown of Sirt1 alone (Figure 
3.11A). These results again suggested that Sirt1 antagonizes Sharp-1 to 
regulate p53.   
In order to determine whether Sirt1 and Sharp-1 antagonize each other to 
modulate p53 dependent senescence under genotoxic stress, cells treated with 
etoposide were seeded for senescence assays. Knockdown of Sharp-1 resulted 
a reduced senescence compared with control cells treated etoposide, whereas 
knockdown of Sirt1 resulted in an increased number of senescent cells. 
Knockdown of Sirt1 in cells that were deficient of Sharp-1 resulted an 
increased number of senescent cells compared with knockdown of Sharp-1 
alone, but the number was lesser compared with knockdown of Sirt1 alone 
(Figure 3.11B). This assay results further supports the idea that Sirt1 
antagonizes Sharp-1 induced p53 expression and function.  
 
A.  






     





Figure 3.11 Antagonism between Sirt1 and Sharp-1 in mediating cellular 
senescence under genotoxic stress.  NIH3T3 cells were co-transfected with 
siSirt1 and siSharp-1 either individually or together. After 48 hours of 
transfection, cells were exposed in the presence or absence of 20 µM 
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etoposide for 2 hours prior to harvest. (A) Cell lysates were analyzed by 
western blot to check for the expressions of endogenous Sirt1 and Sharp-1 
levels with anti-Sirt1 and anti-Sharp-1 antibodies. In addition, acetyl and total 
p53 levels were also determined by anti-AcK379 p53 and anti-p53 antibodies. 
(B) Senescence assays were performed with these cells with or without 
etoposide treatment and SA-ß-gal staining was used to identify the positive 
senescent cells after culturing for seven days. (C) Quantification of percentage 
of SA-ß-gal positive cells was plotted in bar chart and asterisk indicates 
significance values (p < 0.05). 
 
 
3.12 Molecular mechanisms underlying antagonism between Sirt1 and 
Sharp-1 in regulation of p53 
Since Sirt1 and Sharp-1 directly interact with each other and both of them also 
associate with p53, it is possible that Sirt1 and Sharp-1 compete to bind to p53 
and thereby alter p53 acetylation and thus p53 mediated biological functions.  
3.12.1 Sharp-1 does not affect Sirt1-p53 interaction  
We tested whether Sharp-1 enhanced p53 level by dissociation of Sirt1 from 
p53. If Sharp-1 causes dissociation between Sirt1 and p53, then Sirt1 would 
not be able to deacetylate p53. As a result, both acetylated p53 and total levels 
should increase.  
To assess this possibility, NIH3T3 cells were co-transfected with both FLAG-
Sirt1 and p53 expressing plasmid in the presence or absence of Myc-Sharp-1. 
24 hours after transfection, cells were collected and lysed. Expression of 
FLAG-Sirt1, p53 and Myc-Sharp-1 were determined by western blot analysis. 
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Cell lysates were then immunoprecipitated with anti-FLAG agarose beads and 
analyzed using western blot with anti-p53 antibody. Co-immunoprecipitation 
results showed that the presence of Myc-Sharp-1 did not alter the interaction 
between Sirt1 and p53 compared with the interaction between Sirt1 and p53 in 
the absence of Sharp-1 (Figure 3.12.1). Therefore, these data suggest that 
Sharp-1 mediated increase in p53 levels is not due to dissociation of Sirt1 
from p53.  
 
Figure 3.12.1 Sharp-1 does not affect interaction between Sirt1 and p53. 
NIH3T3 cells were co-transfected with FLAG-Sirt1 and p53 in either the 
presence or absence of Myc-Sharp-1. Lysates were immunoprecipitated with 
anti-FLAG agarose beads and detected for p53 levels using anti-p53 antibody. 
Expression of p53, FLAG-Sirt1 and Myc-Sharp-1 was checked with anti-p53, 




3.12.2 Sirt1 does not alter the interaction between Sharp-1 and p53  
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Since Sharp-1 is unable to weaken the binding between Sirt1 and p53, we next 
examined whether Sirt1 disrupts the association between Sharp-1 and p53. 
NIH3T3 cells were co-transfected with both Myc-Sharp-1 and p53 in the 
presence or absence of FLAG-Sirt1. Cells were harvested and lysed after 24 
hours of transfection.  The expression of p53, Myc-Sharp-1 and FLAG-Sirt1 
was determined by western blot analysis. Cell lysates were then 
immunoprecipitated with anti-Myc agarose beads and analyzed using western 
blot with anti-p53 antibody. Co-immunoprecipitation data indicated the 
presence of FLAG-Sirt1 did not alter the association between Sharp-1 and p53 
(Figure 3.12.2). Altogether, our data showed neither Sirt1 nor Sharp-1 
antagonize each other through simple protein-protein association and 
dissociation under normal conditions. 
 
Figure 3.12.2 Sirt1 does not alter Sharp-1 and p53 association. NIH3T3 
cells were co-transfected with Myc-Sharp-1 and p53 in either the presence or 
absence of FLAG-Sirt1. Lysates were immunoprecipitated with anti-Myc 
agarose beads and detected for p53 levels using anti-p53 antibody. 
Expressions of p53, FLAG-Sirt1 and Myc-Sharp-1 were checked with anti-
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3.13 Sirt1 dissociates from Sharp-1 and p53 complex under stress 
conditions 
3.13.1 Sirt1 dissociates from Sharp-1 under DNA damage  
The interaction between DBC1 and Sirt1 increases under DNA damage and 
oxidative stress conditions which in turns inhibits Sirt1 activity. As a result, 
Sirt1 is unable to inhibit p53 mediated biological functions following 
genotoxic stress (Yuna et al., 2012). This study prompted us to investigate 
whether Sirt1-Sharp-1 interaction could be affected by DNA damage. To test 
this, NIH3T3 cells were co-transfected with both FLAG-Sirt1 and Myc-Sharp-
1 which were then treated with or without 20 µM of etoposide for 2 hours. 
Lysates were collected and expression of Sirt1 and Sharp-1 was checked by 
western blot analysis prior to immunoprecipitation with anti-FLAG agarose 
beads. The interaction between FLAG-Sirt1 and Myc-Sharp-1 was determined 
by western blot using anti-Myc antibody. The association between Sirt1 and 
Sharp-1 was weakened following DNA damage (Figure 3.13.1).  
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Figure 3.13.1 Interaction between Sirt1 and Sharp-1 was weakened upon 
DNA damage. NIH3T3 were co-transfected with FLAG-Sirt1 and Myc-
Sharp-1. 24 hours after transfection, cells were exposed in the presence or 
absence of etoposide (20 µM) for 2 hours before harvesting. Expression of 
FLAG-Sirt1 and Myc-Sharp-1 was determined by western blot analysis. 
Lysates were immunoprecipiated with anti-Myc agarose beads and the 
association between Sirt1 and Sharp-1 was checked using anti-FLAG antibody. 
Anti-Myc antibody was used to verify the pull-down materials were equal.  
 
 
3.13.2 Sirt1 dissociates from p53 under genotoxic stress 
As the interaction between Sirt1 and Sharp-1 becomes weaker upon DNA 
damage, we speculated that Sirt1 also dissociates from p53 under stress 
conditions which in turn enhances p53 acetylation. To test this, NIH3T3 cells 
were co-transfected with FLAG-Sirt1 and p53. 24 hours after transfection, 
cells were treated with or without 20µM etoposide for 2 hours prior to harvest. 
Expression of FLAG-Sirt1 and p53 were determined by western blot analysis 
using anti-FLAG and anti-p53 antibodies. ß-actin was used to normalize 
loading of samples. Lysates were then immunoprecipiated with anti-FLAG 
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agarose beads and binding between Sirt1 and p53 was checked by anti-p53 
antibody. In addition, p53 at K379ac was also examined using anti-p53 
AcK379 antibody. Co-immunoprecipitation results supported our idea in 
which Sirt1 indeed dissociated from p53 under etoposide treatment (Figure 
3.13.2).  
 
Figure 3.13.2 Interaction between Sirt1 and p53 is weakened upon DNA 
damage. NIH3T3 were co-transfected with FLAG-Sirt1 and p53. 24 hours 
after transfection, cells were exposed in the presence or absence of etoposide 
(20 µM) for 2 hours before harvesting. Expression of FLAG-Sirt1 and p53 
were determined by western blot analysis. Lysates were immunoprecipiated 
with anti-FLAG agarose beads and the association between Sirt1 and p53 was 
checked using anti-p53 antibody. Anti-FLAG antibody was used to ensure 
pull-down material was equal. 
 
 
3.13.3 Sharp-1 binding to p53 is increased upon genotoxic stress 
Sharp-1 is a stress response protein which gets up-regulated under genotoxic 
stress (Liu et al., 2010).  Since we have demonstrated that Sirt1 dissociated 
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from p53 under stress conditions, next we wanted to examine whether Sharp-1 
p53 association is altered in response to DNA damaging agents. NIH3T3 cells 
were co-transfected with both Myc-Sharp-1 and p53. Cells were treated with 
etoposide (20 µM) for 2 hours before lysis. Lysates were checked for protein 
expressions and then immunoprecipitated with anti-Myc agarose beads. The 
association between Sharp-1 and p53 was checked by anti-p53 antibodies. 
Western blot results supported our speculation as a stronger interaction 
between Sharp-1 and p53 was detected upon stress stimuli. Moreover, acetyl 
p53 also was enhanced due to stronger association between Sharp-1 and p53 
after DNA damage (Figure 3.13.3). Together our data support our hypothesis 
that Sharp-1 and Sirt1 antagonize each other to regulate p53 functions via 
altered protein-protein associations under stress conditions. 
 
Figure 3.13.3 Interaction between Sirt1 and p53 is weakened upon DNA 
damage. NIH3T3 were co-transfected with Myc-Sharp-1 and p53. 24 hours 
after transfection, cells were exposed in the presence or absence of etoposide 
(20 µM) for 2 hours before harvesting. Expressions of Myc-Sharp-1 and p53 
were determined by western blot analysis. Lysates were immunoprecipiated 
with anti-Myc agarose beads and the association between Sharp-1 and p53 
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was checked using anti-p53 antibody. Anti-Myc antibody was used to ensure 
pull-down materials were equal. 
 
 
Based on these interaction data, we suggest that the antagonistic effect 
between Sirt1 and Sharp-1 in p53 regulation is modulated when cells are 
exposed to cellular stress conditions. Sirt1 dissociates from Sharp-1-p53 
complex and Sharp-1 binds to p53 more strongly to increase p53 levels as well 
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4. Discussion 
In the present study, we have found that the basic helix-loop-helix orange 
(bHLH-O) transcription factor Sharp-1 induces p53 dependent premature 
senescence in mouse fibroblast cells which is counteracted by Sirt1, a NAD
+
 
dependent class III histone deacetylase (HDAC).  
NIH3T3 have been used for cellular senescence studies by various groups. For 
instance, overexpression of p21 or oxidative stress in NIH3T3 cell line was 
shown to lead premature senescence in NIH3T3 cells (Chen et al., 2002; Li et 
al., 2008; Dasari et al., 2006). Besides the ease of overexpression of proteins 
of interest, NIH3T3 cells bypass replicative senescence as these are 
immortalized cells. As a result, NIH3T3 cell line is a good model for 
premature senescence (Hsu et al., 2012; Rizzo et al., 2011). We therefore, 
used NIH3T3 in this study as it eliminates confounding factors of replicative 
senescence and ensures that any impact is a direct result of Sharp-1 on 
premature senescence.   
Consistent with a previous study from our group showing Sharp-1 leads to S 
and G2/M cell cycle arrest when overexpressed in NIH3T3 cells cells (Liu et 
al., 2010), we demonstrate that overexpression of Sharp-1 represses cellular 
growth. As growth arrest is one of the hallmarks for cellular senescence, we 
test the ability of Sharp-1 in induction of cellular senescence. Our data show 
that Sharp-1 overexpressing cells indeed undergo cellular senescence with 
concomitant increase of intracellular ROS levels. It is reported that 
accumulation of low concentration of intracellular ROS levels triggers cellular 
senescence by increasing the level of tumor suppressor p53 and activates p53 
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dependent cell cycle regulator p21 involved in G1 arrest (Colavitti and Finkel, 
2005). Moreover, Sharp-1 has been suggested to act as a metastasis suppressor 
(Sermeus and Michiels, 2011). Mutation of p53 facilitates TGF-ß dependent 
migration by inhibiting transcription of metastatic suppressor TAp63 (Beaudry 
et al., 2010), resulting in downregulation of its target gene, Sharp-1. 
Knockdown of Sharp-1 resembled mutant-p53, which increased migration and 
metastatic ability in different breast cancer lines (Melino, 2011).  Our data has 
shown that Sharp-1 has the ability to increase intracellular ROS levels and 
studies have demonstrated that p53 acts as a critical regulator in cellular 
senescence caused by ROS (Bond et al., 1994; Vaziri, 1997; Alimonti et al., 
2010; Serrano et al., 1997). Based on these, we hypothesized that p53 might 
be involved in Sharp-1 mediated cellular senescence. Here, we have shown 
that Sharp-1 induced cellular senescence indeed is p53-dependent as 
knockdown of p53 significantly reduces Sharp-1 dependent senescence. We 
also demonstrate that Sharp-1 might regulate p53 in a positive way as both 
acetylated and total levels of p53 increase in a Sharp-1 dose dependent manner. 
In addition, our data suggest that enhanced intracellular ROS levels induced 
by overexpression of Sharp-1 at least partially contributes to the cellular 
senescence that is mediated by Sharp-1.  
It is well established that p53 undergoes post-translational modifications in 
order to be active and functional. Acetylation by either PCAF or CBP/p300 is 
one major modification which stablizes p53 and increases its transcriptional 
activity and biological functions such as cellular senescence. Conversely, 
deacetylation inhibits p53 activity as well as p53 dependent biological 
functions. Being a deacetylase, Sirt1 deacetylates both histone and non-histone 
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targets. Reports have demonstrated that Sirt1 directly binds to p53 and 
deacetylates it at K379 (Luo et al., 2001; Varizi et al., 2001) which then 
inhibits p53 mediated cellular senescence. In addition, Sirt1 is known to 
reduce ROS levels by increasing catalase expression (Hasegawa et al., 2010). 
We therefore hypothesized that Sirt1 antagonizes sharp-1 mediated cellular 
senescence.  
Indeed, a major finding in this study is the demonstrations that Sirt1 
antagonizes Sharp-1 mediated p53-dependent biological functions as well as 
p53 acetylation at K379. Altering endogenous Sirt1 activity by either its 
activator or inhibitor in the Sharp-1 overexpressing cells  affects both acetyl 
and total p53 levels suggesting that Sirt1 works in the opposite manner in 
Sharp-1 mediated p53 regulation. In addition, overexpressing Sirt1 or 
increasing its activity by resveratrol reduces Sharp-1 mediated senescence 
with decreased acetyl p53 and total p53 levels. These data further support that 
Sirt1 antagonizes Sharp-1 mediated p53 dependent biological function. The 
antagonism between Sirt1 and Sharp-1 is not dependent on transcriptional 
repression of either gene, as overexpression of Sharp-1 does not affect 
endogenous Sirt1 expression and expression of Sirt1 also does not change 
endogenous Sharp-1 at transcription level. However, Sirt1 has the ability to 
deacetylate Sharp-1, though the biological significance is unknown at this 
moment. In addition, knockdown of both Sirt1 and Sharp-1 strongly supports 
the notion that Sirt1 and Sharp-1 antagonism impact p53 expression and 
cellular senescence under genotoxic stress.   
To address the mechanisms underlying the antagonism between Sharp-1 and 
Sirt1 in regulation of p53, we first examined Sharp-1 association with Sirt1 by 
- 106 - 
 
co-immunoprecipitaiton (Co-IP) assays. Co-IP data and co-localization results 
validate that both proteins interact and are localized in nucleus. Using GST-
pull down assay, we also demonstrate that Sharp-1 directly interacts with Sirt1. 
In addition, various Sharp-1 mutants are created in our lab and we further 
define that Sharp-1 associates with Sirt1 through a region containing the 
bHLH domain. Our data are in line with findings from Kato’s group in which 
they show Dec2, a human homolog of Sharp-1, to interact with Sirt1 through 
the bHLH domain (Fujimoto et al., 2007).  
Moreover, Sharp-1 is able to interact with p53. Since previous studies have 
demonstrated that Sirt1 binds to p53, we reasoned that if Sirt1 antagonizes 
Sharp-1 mediated p53 dependent functions, overexpression of either Sirt1 or 
Sharp-1 may weaken the binding between the two other proteins. However, 
our data show otherwise, i.e., overexpression of Sirt1 does not break the 
interaction between Sharp-1 and p53; nor does Sirt1 dissociation from p53 in 
the presence of Sharp-1.  
Recent studies have demonstrated that Sirt1 dissociates from p53 and binds to 
its negative regulator, DBC1, more tightly in cells with DNA damage (Zannini 
et al., 2012). In addition, Sharp-1 is up-regulated upon DNA damage (Liu et 
al., 2010). We therefore tested whether the association between Sirt1 and p53 
is weakened, and the interaction between Sharp-1 and p53 is enhanced under 
stress conditions. Indeed, co-immunoprecipitation results support the idea. 
Sirt1 dissociates from p53 under etoposide treatment, whereby the association 
between Sharp-1 and p53 is increased in the presence of etoposide. In addition, 
Sirt1 also dissociates from Sharp-1 under genotoxic stress. Collectively, our 
results suggest the increased p53 acetylation at K379 in response of DNA 
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damage in cells is due to up-regulated Sharp-1 and enhanced Sharp-1 and p53 
interaction, as well as through dissociation of Sirt1 from p53.  
Taken together, our results indicate that overexpression of Sharp-1 induces 
growth arrest and cellular senescence which are p53 dependent in fibroblast 
cells. In addition, Sirt1 antagonizes Sharp-1 induced growth arrest and 
senescence that is concomitant with reduced acetyl and total p53 levels. We 
thus propose a model for the antagonistic effect between Sharp-1 and Sirt1 in 
regulation of p53-mediated biological functions. In this model, Sharp-1 
dissociates from Sirt1 under genotoxic stress, resulting up-regulation of its 
activity. In addition, binding between Sharp-1 and p53 enhances and thus 
promotes acetylation on p53 at K379. Moreover, the binding between Sirt1 
and p53 weakens under DNA damage which makes p53 even more acetylated 
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Figure 4.1 Proposed model of Sirt1 dependent antagonism of Sharp-1 
mediated cellular senescence.  Sirt1 modulates Sharp-1 enhanced p53 acetyl 









CONCLUSION AND FUTURE STUDIES 
  
- 109 - 
 
5. Conclusion and Future Studies 
The research work presented here examines possible mechanisms underlying 
the tumor suppressor role played by Sharp-1 in fibroblast cells. My results 
have demonstrated that Sharp-1 mediated cellular senescence is p53 dependent 
and Sharp-1 enhances p53 levels. In addition, my work also explores the 
previously not well understood biological significance of the interaction 
between Sharp-1 and Sirt1 as I have shown that Sharp-1 and Sirt1 antagonize 
each other to modulate p53 acetylation and thus p53 mediated physiological 
functions.  
Though I have demonstrated that Sirt1 and Sharp-1 function in an opposite 
manner to regulate p53, the exact mechanisms on how Sirt1 antagonizes 
Sharp-1 enhanced p53 acetyl level needs to be further elucidated. To 
investigate this, it would be important to determine how exactly Sharp-1 
increases p53 acetyl levels. It is well known that post-translational 
modifications lead to p53 stability and activation. In particular, acetylation of 
lysine residues in the C-terminus of p53 by both acetyl-transferases P/CAF 
and CBP/p300 increase its DNA-binding activity and stability (Ito et al., 2001; 
Gu and Roeder, 1997; Liu et al., 1999).  Since Sharp-1 increases p53 
acetylation at K379, it is possible that Sharp-1 has the ability to recruit acetyl-
transferase CBP/p300 to the C-terminus of p53. Co-immunoprecipitation 
assays would be carried out to check for the possible interaction between 
Sharp-1 and CBP/p300 and examine acetyl p53 K379 in the presence or 
absence of CBP/p300. 
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p53 is regulated by preventing it from nuclear export and Mdm2-mediated 
proteasomal degradation (Thin et al., 2007). To test whether Sharp-1 prevents 
p53 from Mdm2-mediated degradation, we could express p53 with Mdm2 in 
the presence of increasing amount of Sharp-1 as described (Thin et al., 2007) 
in presence of the proteasome inhibitor N-acetyl-leucyl-leucyl-norleucinal 
(ALLN) to prevent p53 degradation prior to lysis. Cell lysates can be analyzed 
by western blot to detect ubiquitinated p53 with anti-p53 antibody. If Sharp-1 
protects p53 from Mdm2-mediated degradation, the ubiquitinated p53 levels 
should decrease with increasing amount of Sharp-1.  
My results have indicated that Sirt1 and Sharp-1 antagonize each other to 
modulate p53 acetylation. However, neither Sirt1 nor Sharp-1 affects one 
another’s expression. In addition, being a deacetylase, I have shown that Sirt1 
indeed deacetylates Sharp-1, though the functional significance is not clear at 
this point. My hypothesis is that deacetylation of Sharp-1 by Sirt1 reduces its 
ability to recruit acetyl transferases. As a result, reduced acetyl p53 levels may 
be due to reduced association of CBP/p300 with p53. Thus, it will be 
meaningful to investigate whether recruitment of CBP/p300 by Sharp-1 to p53 
is dampened in the presence of Sirt1 due to deacetylation. On the other hand, 
since Sirt1 requires NAD
+
 to function, and overexpression of Sharp-1 
increases p53 acetylation, it will be interesting to test whether NAD
+
 level is 
altered in Sharp-1 expressing cells since reduced NAD
+
 lower Sirt1 activity 
results in less deacetylated p53.  
Taken together, this research work provides possible mechanisms by which 
Sirt1 antagonizes Sharp-1 mediated p53 acetylation and cellular senescence. In 
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addition, this study also adds an extra level of complexity to the regulation of 
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Table I. Smart pool siRNA Sequences for Non-Targeting siRNA 






























Table II. Smart pool siRNA Sequences for siSirt1 






















Table III. Smart pool siRNA Sequences for siTrp53 





















Table IV. GeneSolution siRNA Sequences for siBHLHB3 






















Table V. Primers for real time PCR (Q-PCR) 
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